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Abstract
Women are more likely to have severe asthma than men. Recent data suggest this could be due
to women having more circulating CD4+CRTh2+ T cells (Th2 cells). Glucocorticosteroids
(GC)s are the main therapy for asthma as they inhibit cytokine production and eliminate
inflammatory cells by apoptosis. The current study examined whether the female sex hormone
estrogen influences the anti-inflammatory action of GC. Experiments show that ERa agonist
reduced GC-induced apoptosis of primary Th2 cells and enhanced GC-mediated
transcriptional activation of the proximal CRTh2 promoter. Genetic variation within CRTh2 is
associated with asthma and allergic phenotypes. Using constructs representing the single
nucleotide polymorphism CRTh2-6388G>A, ERa agonist enhanced GC-induced activity of
the A but not the G allele. Collectively, these data suggest that in vivo Th2 cells may exhibit
sex and genotype specific response to GC and that some of these effects are pro-inflammatory.

Keywords
Asthma, CRTh2, Estrogen signaling, Genetic variation, Glucocorticosteroid, Th2
inflammation
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Summary for Lay Audience
Throughout the world, asthma places a large financial burden on the health care system.
Genetic and environmental factors both play a role in the development of this disorder.
Glucocorticosteroids (GC)s are the main treatment for asthma because of their antiinflammatory action. Despite being effective in most patients, in severe asthmatics GC therapy
fails to control asthma symptoms. Less understood is that GCs can also promote expression of
some immune genes such as CRTh2 (chemoattractant receptor-homologous molecule
expressed on Th2 cells), which supports the survival of Th2 cells. Women are more likely to
be diagnosed with severe asthma and were recently shown to have more circulating Th2 cells
than men. This may be due to estrogen influencing Th2 differentiation or the effect of GC on
Th2 cells. On this basis, it was hypothesized that estrogen reduces the ability of GC to trigger
Th2 cell death, that this occurs by enhancing GC-mediated increase in CRTh2 expressing cells,
and that the outcome of this cross-talk is altered by genetic variation in CRTh2. Results
revealed that the ability of GC to induce Th2 cell death was dampened by co-treatment was
estrogen. Though the mechanism of enhanced survival was not confirmed to be due to
increased expression of CRTh2, results do show that GC activated CRTh2 transcription and
this effect was enhanced by co-treatment with an estrogen receptor agonist. Analysis of the
CRTh2 gene variant CRTh2-6388G>A showed that estrogen enhanced the ability of GC to
induce transcriptional activation of the CRTh2-6388A allele. This study suggests that
combined exposure to GC and estrogen, an environment found in women taking GC for their
asthma, increases Th2 cell survival. If this occurs in vivo, this cross-talk may explain why
women have more Th2 cells and asthma severity than men. Transcriptional activation of
CRTh2 was induced by GC and estrogen in a genotype specific manner. Ultimately, these
results suggest that precision medicine for asthma therapy should consider both sex and CRTh2
genetics.
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Chapter 1

1

Introduction

Sex differences have been reported in various autoimmune and infectious diseases, as well
as inflammatory stress responses. Interestingly, it has been estimated that 78% of
autoimmune patients are women [2, 3]. Additionally, the distribution of the autoimmune
diseases Hashimoto’s thyroiditis, Graves’ disease, systemic lupus erythematosus, and
Sjogren’s syndrome is over 80% female [4]. The progression from the human
immunodeficiency virus (HIV)-1 to acquired immunodeficiency syndrome (AIDS) has
been shown to be faster in women than men despite equivalent blood viral load, an effect
mediated by continuous immune activation [5].
There are also sex differences in the prevalence and severity of asthma [6], though the
pathobiology is poorly understood. Interestingly, our laboratory has observed that women
with severe asthma have significantly higher levels of pro-inflammatory CD4+ T cells
expressing CRTh2 (Th2 cells) than patients with mild or moderate asthma and severe
asthmatic men (App. 1.1). Despite the use of glucocorticosteroids (GC) to alleviate the
underlying inflammation causing asthma symptoms, many women are resistant to this
treatment [7]. This may be due to altered responsiveness of their Th2 cells to the effects of
GC since a positive association between the total daily dose of inhaled corticosteroids and
the proportion of circulating Th2 cells was found in women but not men (App. 1.2).
Activation of CRTh2 inhibits Th2 cell apoptosis [8] and so factors that increase its
expression may enhance Th2 cell survival. To continue this line of investigation, the
current study examined if estrogen could reduce GC-mediated apoptosis by increasing
expression of CRTh2. Additionally, whether a CRTh2 genetic variant associated with
asthma severity and increased CRTh2 influences this regulatory pathway was examined.
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1.1 Development of Allergic Asthma
Asthma is a chronic inflammatory disease that affects 300 million people worldwide; it is
thought to be one of the most common chronic diseases [9]. Understanding the origin of
asthma is an active area of research, and crucial for understanding my study. Interactions
between genes and environmental factors also mediate asthma susceptibility [10, 11]. Gene
polymorphisms, such as that of a disintegrin and metalloproteinase 33 (ADAM33), have
been associated with asthma pathogenesis [12]. Individuals have a 25% or 50% likelihood
of developing asthma if one or both parents, respectively, have asthma [13]. Additionally,
monozygotic twins have a higher risk compared to dizygotic twins of having asthma if one
twin is affected, highlighting the important role of genetics in development of allergic
asthma [14]. However, the development in monozygotic twins is only 75%, indicating that
environmental factors indeed interact [13]. Certain genes associated with risk of
developing allergic disease are only expressed upon certain environment exposures;
filaggrin mutations related to eczema development are enhanced by cat exposure in
children [15].
Asthma is characterized by bronchial constriction, mucus production and airway
obstruction. Clinically, patients present with symptoms of wheezing, chest tightness,
shortness of breath and coughing, all of which vary in intensity and severity [16]. These
indications require costly acute care and have potential to cause death [17]. The
development and expression of asthma are influenced by host factors, such as sex, genetic
variation and obesity, as well as the environment, allergens, pollutants, viral infection,
tobacco smoke, stress and exercise [18].
Asthma can be allergic or non-allergic contingent on the presence of allergic sensitization
[19]. Allergic asthma often begins in childhood and is characterized by eosinophilic
inflammation and an increase in T helper (Th) 2 cells and Th2 cytokine responses [20-22].
Conversely, non-allergic asthma is often characterized by neutrophilic inflammation [23],
Th1 cells and Th1 responses [24]. Understanding the mechanisms underlying development
of these different immune responses and their influence on asthma phenotype is an active
area of research and relevant to this thesis.
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1.1.1

Innate vs Adaptive Immunity

Asthma arises as a combined result of inhaling foreign particles from the environment
(allergen, pollution, virus) and the individual’s response to this exposure. The immune
system uses both innate and adaptive immunity to combat against foreign entities. The
innate component is the first line of defense to mount a response to pathogens, using pattern
recognition receptors to initiate rapid inflammatory responses; dysfunction in airway
epithelial cells may play a role in asthma [25, 26]. In contrast, the adaptive immune
response is highly specific towards the directed antigen. Epithelial cells within the mucosal
lining interact with dendritic cells to activate T lymphocytes and trigger the development
of specialized subsets of memory T cells [26]. T cells in turn interact with B cells to mediate
development of antigen-specific immunoglobulin (Ig) responses. Although innate
immunity is important, the focus of my study is on T cells and their potential role on
persistence of asthma.

1.1.2

Antigen Presentation

Antigen presenting cells (APC), such as dendritic cells, macrophages, and B cells,
recognize, process and present antigens to T lymphocytes. This is an initial process in
adaptive immunity of asthma. Dendritic cells are professional APC and are responsible for
sensitization and stimulation of naïve T cells [27]. Macrophages, the most abundant
leukocyte in the conducting airways [28], have also been shown to be antigen-presenting
[29], but function in a variety of other capacities, such as in innate defense mechanisms
and facilitating T-lymphocyte proliferation [30]. Dendritic cells use phagocytosis or
receptor mediated endocytosis to take up the allergen (antigen) [31] and exposure to
pathogen-associated molecular pattern (PAMP)s activates their maturation. This involves
upregulation of cluster of differentiation (CD) 80 and CD86 [32] and C-C chemokine
receptor type 7 (CCR7) [33], which induce the dendritic cells to migrate to lymph nodes
[34]. Maturation of dendritic cells can also be promoted by interleukin (IL) -33, thymic
stromal lymphopoietin (TSLP) and IL-25 secreted by the epithelium [35-37]. Following
maturation, these dendritic cells will process the allergen into a peptide and present it on
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major histocompatibility complexes (MHC) class II molecules to the T-cell receptor (TCR)
on naïve CD4+ T cells in the lymph nodes [38, 39]. This binding along with co-stimulation
of CD80 and/or CD86 binding to CD28, fully activates the naïve CD4+ T cell [40, 41].

1.1.3

CD4+ T Lymphocytes

CD4+ T lymphocytes have numerous functions including producing cytokines and
activating innate immune cells. It is now appreciated that CD4+ T cells can develop into a
number of subsets including, but not limited to: induced regulatory T (iTreg) cells, T
follicular helper cells (Tfh), Th1, Th2, and Th17 cells. Although the focus of my study is
on Th2 cells, the asthmatic response does involve numerous other cells. Differentiation
depends on the antigen concentration and cytokine microenvironment: transforming
growth factor (TGF)-b and IL-2 for iTregs, IL-6 and IL-21 for Tfh, interferon (IFN)-g and
IL-12 for Th1, IL-2 and IL-4 for Th2 and IL-23 and IL-17 for Th17 cells [41-46].

1.1.4

Th1:Th2 Dichotomy

Naïve CD4+ T cells making direct contact with dendritic cells causes tubulin fibers to
deliver antigen specific MHC class II into the centre of the contact synapse [47]. The
strength of the TCR cross-linking will direct differentiation; moderate stimulation will lead
to Th2 cells, whereas strong stimulation will favor Th1 cell development [48].
Th1 cells are responsible for intracellular microorganism immunity, whereas Th2 cells
provide extracellular pathogen immunity [49]. Originally, mature CD4+ T cells were
discovered to be made up of two distinct Th populations with unique functions [49]. They
were categorized by their ability to produce IL-4, IL-2 and/or IFN-g; Th2 cells produce IL4, whereas Th1 cells cannot [50], but unlike Th2 cells, Th1 cells can produce IL-2/IFN-g
[49]. Later it was determined that differentiation into the subtypes was largely dependent
on activated transcription factors. T-box transcription factor (T-bet) enhances the
production of IFN-g leading to the differentiation into the Th1 subset, and also suppresses
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the development of Th2 and Th17 [51, 52]. Th1 differentiation is also dependent on the
transcription factor signal transducer and activator of transcription (STAT)1 and STAT4,
transducers of the IFN-g and IL-12 receptors [53, 54].
In contrast to Th1 cells, Th2 differentiation is mediated by STAT6 and GATA3 [55-57].
Both differentiation pathways use positive feedback mechanisms, and are mutually
inhibitory. Th1 cells secrete IFN-g which further promotes Th1 and inhibits Th2
differentiation [58]. Similarly, Th2 cells secrete IL-4, which inhibits Th1 development but
promotes Th2 [58]. Microenvironments that drive Th1 cells primarily include the cytokines
IL-2 and IFN-g, acting to activate macrophages, increasing their microbial activity [59];
whereas, Th2 microenvironments primarily include IL-4, promoting Th2 cell
differentiation and mediating IgE switching in B cells [45, 60].

1.1.5

Th2 Cell Differentiation

Th2 cell differentiation is initiated by CD3 and CD28 crosslinking, which induces the
downstream signaling cascade that will induce the activation of nuclear factor of activated
T cells (NFAT) and activator protein (AP)-1 [61], the production of IL-2 and low levels of
IL-4 [62]. IL-4 will then bind to the IL-4R, activating STAT6, which increases GATA3
and leads to higher IL-4 production and Th2 differentiation [55, 63]. TCR activation will
also upregulate GATA3; however, the binding of GATA3 to the Il4/Il13 loci is not enough
to induce alone, rather IL-2 activated STAT5 must be present to maintain the accessibility
of the Il4 locus [64, 65]. The combined presence of GATA3 and STAT6 will also induce
chromatin remodeling, increasing the accessibility of the IL-4 enhancer and genes that
regulate maintenance of the Th2 phenotype [66] such as CRTh2 [67, 68].
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1.1.6

Type 2 Inflammation

In addition to allergens, pollutants, such as cigarette smoke, diesel exhaust, and viral
exposure can prompt the production of IL-25, IL-33 and TSLP, further inducing IL-13
production, IL-4 and -5 production, and Th2 cell differentiation, respectively [69-72].
Additionally, IL-33 stimulates group 2 innate lymphoid cells (ILC2) to secrete IL-13,
promoting dendritic cell migration to the lymph nodes for Th2 differentiation [73, 74].
Therefore, type 2 inflammatory responses can be orchestrated through allergic sensitization
or other environmental exposures, carried out by both Th2 and ILC2 cells [75].
Figure 1.1 provides a schematic representation of the type 2 cytokines IL-4, -5, and -13
play and their role in driving asthmatic symptoms. IL-5, produced by Th2 cells [76],
increases the production of eosinophils in the bone marrow, as well as heightens airway
sensitivity [77, 78]. The cytokine IL-13 plays a large role in asthma, activating eosinophils,
increasing mucus secretion, inducing hyper-responsiveness in the airway and causing
bronchial constriction [79, 80]. The alpha subunit of the IL-4 receptor (IL-4Ra) is part of
both IL-4R and IL-13R complexes, implicating their shared roles [81]. IL-4 induces IgE
secretion by inducing B cells to initiate isotype switching to IgE production [82]. IgE can
then bind to both low-affinity IgE receptor (fragment crystallizable (Fc)eRI) on B cells and
high affinity IgE receptor (FceRII) on mast cells and basophils; both receptors are
upregulated by IL-4 [83]. Upon allergen exposure, mast cells primed with IgE will
degranulate, releasing mediators such as histamines and prostaglandins [84, 85]. Both IL5 and IL-13 are important mediators in driving features of asthma such as tissue
eosinophilia, airway remodeling and increased mucous production [80]. Due to the role
these cytokines play in asthma, IL-4, -5 and -13 targeted treatments have been recently
developed and shown to relieve symptoms associated with asthma [86-88].
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Figure 1.1: Type 2 Inflammatory Response to Allergen
Allergen presentation by dendritic cells to Th2 cells induces production of the type 2
cytokines IL-4, -5, and -13. Type 2 cytokines mediate allergic inflammation. IL-13 induces
bronchial constriction, excess mucus production and in combination with IL-5 activates
eosinophils. IL-4 induces B-cells to produce IgE that will bind and prime mast cells. Upon
allergen exposure, primed mast cells will degranulate and release mediators such as PGD2
which binds to the receptor CRTh2 expressed on Th2 cells and eosinophils. Abbreviations
are as follows: antigen presenting cells, APC; chemoattractant receptor-homologous
molecule expressed on Th2 cell, CRTh2; interleukin, IL; prostaglandin D2, PGD2; T helper
cell type 2, Th2. Created with BioRender.com.
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1.2 Regulation and Function of Chemoattractant ReceptorHomologous Molecule Expressed on Th2 Cells
In 1999, Nagata and colleagues performed a subtractive hybridization screen for
differentially expressed genes between Th1 and Th2 cells. They found a G protein-coupled
receptor expressed by Th2 cells, but not Th1 cells [89]. They named this gene
chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTh2), due to
its homology to other receptors with chemotactic activity [89, 90]. Since this discovery
CRTh2 has also been shown to be expressed by eosinophils, basophils, ILC2 and mast cells
[91-94]. However, expression of CRTh2 within the CD4+ T cell subset is considered the
most reliable marker of Th2 cells [95]. GATA3, increased through the IL-4 dependent
STAT6 induction, increases CRTh2 promoter activity [96], however, little else is known
regarding the transcriptional regulation of this important Th2 gene.

1.2.1

CRTh2 and Allergic Disease

CD4+ T cells expressing CRTh2 are considered Th2 cells and studies show they are
increased in individuals with atopic dermatitis as well as allergic asthma [97, 98]. Elevated
levels of CRTH2 transcripts in bronchoalveolar lavage (BAL) fluid were found in severe
asthmatics compared to those with mild/moderate asthma [98]. Moreover, a positive
association was found between asthma exacerbations, poor control or Th2 cytokines, and
CRTH2 levels [98]. Our laboratory has also reported an increased proportion of circulating
CD4+CRTh2+ T cells in severe asthmatics compared to those with mild or moderate asthma
[99].

1.2.2

Genetic Variation within CRTh2

The CRTH2 gene is located on chromosome 11q12-13 [90]. Numerous single nucleotide
polymorphisms (SNPs) within the CRTH2 gene locus have been associated with allergic
asthma and sensitization, as well as higher bronchial hyper-responsiveness, in ethnically
distinct populations (ie. Chinese and African American) [100, 101]. Genetic variation
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within a German population of children has also been associated with the development of
allergic sensitization and asthma [102]. A specific example is CRTh2 -6388G>A
(rs533116); our group has shown that individuals with the AA genotype had increased
CRTh2 expression, higher levels of circulating eosinophils, enhanced Th2 differentiation
and cytokine production compared to those of the GG genotype [103].

1.2.3

Functional Outcomes of PGD2 Activation of CRTh2

Prostaglandin D2 (PGD2) is a ligand for CRTh2 [89, 104]. It is considered the second Dprostanoid receptor (DP2) for PGD2 [105]. PGD2 is a metabolite derived from the
conversion of arachidonic acid to prostaglandin endoperoxide H2 (PGH2) by
cyclooxygenases, where it acts as a substrate to PGD synthase, a catalyst to the conversion
to PGD2 [106, 107]. Following exposure, allergen crosslinking of two IgE molecules
activates mast cells to degranulate and release the lipid mediator, PGD2 [84, 85]. Indeed, it
has been shown that CRTh2 activation by PGD2 mediates the mobilization of intracellular
calcium [108], phosphatidylinositol 3-kinase (PI3K) phosphorylates protein kinase B
(Akt), nuclear factor of activated T-cells (NFAT) translocate into the nucleus and drives
type 2 cytokine gene expression [61, 109]. PGD2 activation of CRTh2 is known to mediate
pro-inflammatory response in allergic disease, as supported by in-vivo mouse models of
atopic dermatitis and allergic asthma, demonstrating that ovalbumin (OVA) challenged
mice that were nebulized with a CRTh2 specific agonist (DK-PGD2) had increased
eosinophilia compared to vehicle-treated mice [110]. In human cells, many of the
mechanisms have been worked out in-vitro [111].
One functional outcome of PGD2 activation of CRTh2 is the mediation of chemotaxis of
Th2 cells, eosinophils and basophils [104]. Mechanistically, this interaction activates
PI3Kg, leading to Akt phosphorylation, and further actin polymerization [109]. Studies
have found that antagonizing CRTh2 inhibited chemotaxis [112], as did phosphoinositide
3-kinase (PI3K) inhibition, confirming the signaling pathway [109].
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Studies have shown that activation of CRTh2 increased the type 2 pro-inflammatory
cytokines, IL-4, -5, and -13 [68, 113]. This effect is dependent on calcium activated
calcineurin, further dephosphorylating and activating NFAT to allow for translocation into
the nucleus and cytokine gene transcription [109]. Therefore, blocking PI3K and calcium
(Ca2+) pathways has been shown to reduce cytokine production, as does the CRTh2
antagonist Ramatroban [68, 109].
IL-2 is an important survival and growth factor for T cells [114] and so deprivation of this
cytokine triggers T cell apoptosis [115]. Interestingly, the binding of PGD2 to CRTh2 has
been shown to inhibit Th2 apoptosis. Indeed, the addition of PGD2 significantly reduced
the percentage of Th2 cells containing fragments of cleaved cysteine-aspartic protease
(caspase) -3 and poly adenosine diphosphate polymerase (PARP), signatures of death by
apoptosis [8].

1.3 Asthma: A Clinical Perspective
Th2 cells, type 2 inflammation and genetic variation collectively influence the persistence
of asthma symptoms. My study examines how Th2 cells respond to various asthma related
factors and therefore this section provides an overview of asthma diagnosis, subsets of
severity and treatment.

1.3.1

Diagnosis

Diagnosis of asthma is based on clinical symptoms as well as lung function tests. Forced
expiratory volume in the first second (FEV1) is the maximum volume of air expelled from
the lungs in one second of forced expiration, measured through a spirometer [116].
Measurements are taken prior to the administration of 200 to 400 µg of the bronchodilator
albuterol, and 10-15 min post bronchodilator [17]. As asthma is classified as reversible
airflow obstruction, an increase in FEV1 greater than 12% and 200 mL indicates
reversibility, which is consistent with a positive diagnosis [117]. The administration of an
anti-inflammatory controller for four weeks resulting in an improved FEV1 greater than
12% can further confirm this diagnosis [118]. If an increase is not achieved with this
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medication, but the patient presents with characteristics of asthma, a bronchial provocation
test may be used. This test involves administering increasing doses of methacholine to
induce bronchoconstriction; a reduction in FEV1 by 20% with a dose less than 8 mg/mL
indicates hyper-responsiveness characteristic of a positive diagnosis of asthma, compared
to the minimum 16 mg/mL required for a non-asthmatic [119]. Other targeted approaches
are also be used to further characterize the type of asthma, such as airway or sputum
eosinophilia or neutrophilia [120].

1.3.2

Asthma Severity

The Global Initiative for Asthma (GINA) uses symptoms, airflow limitation and lung
function to divide asthma into the categories of intermittent, mild, moderate and severe
persistent [121]. Intermittent asthmatics have symptoms less than 2 days per week with no
activity interference and normal lung function [122]. In contrast, mild, moderate and severe
asthmatics are symptomatic more than 2 days per week, daily, and numerous times
throughout the day, respectively [122]. Exacerbations increase in frequency along the
diagnosis scale; intermittent asthmatics have no exacerbations, whereas severe asthmatics
may have as many as one exacerbation per week [122]. Lung function also deteriorates
along the same scale [122]. The European Respiratory Society (ERS) and American
Thoracic Society (ATS) defines severe asthma as that in which a patient is treated with a
high dose of inhaled glucocorticosteroid as well as a secondary controller, such as a b2adrenergic agonist, to prevent worsening symptoms, but remains uncontrolled despite this
treatment [123]. It is estimated that 5-10% of all asthmatics are classified to have severe
asthma [124]. This phenotype is also predictive of increased hospitalizations [125]. Certain
symptoms associated with severe asthma, such as wheezing and shortness of breath, have
a strong genetic component [126].
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1.3.3

Asthma Treatment

Strategies to reduce the chronic inflammation of asthma and relieve symptoms include
controllers and relievers. Controllers are a long-term therapy, acting to control symptoms
through reducing airway inflammation and preventing exacerbations; inhaled
corticosteroids (ICS), such as budesonide, are a common controller first prescribed upon
diagnosis [127, 128]. Relievers act to immediately relieve symptoms that are worsening
during exacerbation. Both long- and short-acting inhaled b2-adrenergic agonists (LABA,
SABA, respectively), such as formoterol, provide relaxation of bronchospasm [129]. They
are not effective as a monotherapy; rather, most patients with persistent symptoms have
found combination LABA and ICS therapy to be beneficial in improving symptoms,
reducing exacerbations and achieving control of lung function [127, 130-132]. Severe
asthmatics do not experience major benefit from ICS, like mild and moderate asthmatics,
or even long-term oral or parenteral systemic corticosteroid therapy [133]. As such, severe
asthmatics are considered to be less corticosteroid responsive. The mechanism(s) driving
this resistance are not well understood but may be related to Th2 cells and endogenous
factors influencing their function.

1.4 Glucocorticosteroid
Glucocorticoid (GC) and mineralocorticoid are two classes of corticosteroids, responsible
for suppression of inflammation [134] and electrolyte balance [135], respectively. The term
corticosteroid is often used synonymously with GC. The GC, cortisol, is a steroid hormone
synthesized in the adrenal cortex and secreted in the blood in response to stress [136].
Cortisol is the precursor to cortisone, first extracted from the adrenal gland in 1936, and in
1950, found to be beneficial in treating asthma [137, 138]. Since then, synthetic GCs with
higher potencies have been developed and used to treat inflammatory diseases, such as
asthma. The systemic GC prednisolone was originally used in clinical practice for treating
asthma; however, long term use is associated with serious adverse effects such as
cardiovascular disease, osteoporosis, and diabetes [139-141]. This led to the transition of
asthma therapy to inhaled GC [142].
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1.4.1

Mechanism of Action

GCs bind to their cytoplasmic glucocorticoid receptor (GR), a 777 amino acid protein
expressed by nearly all cells in the human body [143]. As a member of the ligand regulated
nuclear receptor family [144], the GR structure consists of three domains: the C-terminal
domain, responsible for steroid (ligand) binding and repressing transcription-activation
until such binding occurs; the conserved central deoxyribonucleic acid (DNA) binding
domain, responsible for dimerization, direct binding to the major groove of DNA, and
transcription-activation through zinc clusters [145-147]; and the N-terminal domain,
required for transcriptional activation [148, 149]. Between the DNA and ligand binding
domains is the hinge-region, which aids in nuclear translocation [150].
Unbound, GR remains inactive within the cytoplasm as a hetero-oligomer, consisting of
chaperone proteins such as heat shock protein (hsp) 90 and FK506 binding protein-5
(FKBP5) [151, 152]. Through passive diffusion, GCs pass through the cytoplasm and bind
directly to the ligand binding domain, inducing a conformational change of the GR and the
dissociation of hsp 90 and FKBP5 [153]. This activation allows translocation of the GCGR complex into the nucleus, where it forms homodimers [153]. This complex is now
capable of regulating gene transcription through a variety of mechanisms (Fig. 1.2).
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Figure 1.2: Glucocorticoid Mechanisms of Action
GC passively diffuses through the cytoplasm and binds to GR, inducing the dissociation of
the chaperone proteins hsp90 and FKBP5 previously bound. The GC-GR complex then
translocates into the nucleus and forms a homodimer. The GC-GR complex can directly
bind to a GRE or nGRE and activate (transactivation) or inhibit (transrepression) gene
transcription, respectively (A). Alternatively, the homodimer can interact with
transcription factors (B) and inhibit their ability to activate transcription through proteinprotein interactions. Competitive interactions can also occur when there are overlapping
glucocorticoid and transcription factor response element sites, therefore the binding of GR
inhibits the binding of the TF. Abbreviations are as follows: CREB binding protein, CBP;
FK506 binding protein-5, FKBP5; glucocorticoid, GC; glucocorticoid receptor, GR;
glucocorticoid response element, GRE; heat shock protein, HSP; interleukin, IL; mitogenactivated protein kinase-1, MKP-1; negative glucocorticoid response element, nGRE;
thymic stromal lymphopoietin, TSLP; transcription factor, TF; transcription factor
response element, TFRE. Created with BioRender.com.
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GC-GR Direct Binding to DNA Sequences
GCs can directly bind to DNA sequences within promoter and regulatory regions entitled
glucocorticoid response elements (GREs); the consensus sequence of a GRE is composed
of the half site AGAACA, followed by 3 nucleotides and the other half site TGTTCT [154].
Direct binding to GREs can induce either transactivation or transrepression (Fig. 1.2A)
[155, 156]. Transactivation is the activation of gene transcription such as the arachidonic
acid inhibitor, p11 [157]. GC can also act through transrepression, the inhibition of
transcription, through interaction with negative GRE sites (nGREs) [158]. It has also been
shown that binding of the GR complex to GRE may alter the conformation of DNA or
chromatin [159]. Activated mitogen-activated protein kinase (MAPK) cascades are key
regulators in the production of pro-inflammatory mediators [160]; however, MAPK
phosphatase 1 (MKP-1) dephosphorylates conserved threonine and tyrosine residues, thus
terminating the MAPK pathway [161]. A GRE is present in the MKP-1 promoter, and GC
binding to this GRE induces this gene, further acting in an anti-inflammatory capacity [162,
163].

GC-GR Interactions with Transcription Factors
GR can also regulate transcription through interactions with transcription factors (TF) (Fig.
1.2B). Many pro-inflammatory genes, such as cytokines, do not have nGREs. Rather, the
GC-mediated effect is through GR interacting with transcription factor binding [164]. For
instance, GR binding to the TFs, nuclear-factor-kB (NF-kB) and activator protein-1 (AP1), represses their ability to activate transcription [165-167]. This can result in the
inhibition of cytokine gene transcription, such as IL-5 and IL-13 [168]. Interestingly,
protein-protein direct interactions between GR and a TF can induce mutual repression of
the protein dependent genes [169]. A competitive GRE occurs where the transcription
factor has an overlapping site for GR, thus GR binding would prevent the positive TF from
activating the gene, as seen in the osteocalcin promoter [170].
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GC-GR Modulation of mRNA Stability
The GC-GR complex is also capable of altering the stability of messenger ribonucleic acid
(mRNA). Shaw et al., found that a conserved region in the 3’ untranslated region (UTR)
contained adenylate-uridylate (AU) rich elements (AREs) implicated in mRNA instability
in human granulocyte-macrophage-colony-stimulating-factor (GM-CSF) [171]. mRNA is
often degraded through shortening of the poly(A) tail by ribonucleases, an effect mediated
by AREs [172]. Moreover, it has been observed that GC enhances the transcription of
ribonucleases capable of degrading AU-rich elements, and selectively decreases the
stability of mRNA for cytokine genes such as IFN-b, and IL-1b [173, 174]. It was also
noted that the 3’ UTR of inflammatory cytokine, lymphokine and growth factor genes also
contain AU-rich elements, indicating a potential mechanism in which GC acts on to
suppress inflammation [175]. Interestingly, GCs have been shown to reduce IL-4Ra
mRNA through destabilization [176], however further studies are required to validate this.

1.4.2

Pro-Inflammatory Effects of GC

While GC are primarily considered anti-inflammatory, there is a growing body of evidence
suggesting they also have pro-inflammatory effects. Indeed, GC has been shown to
increase expression of immune receptors such as IL-2R [177], C-X-C chemokine receptor
(CXCR) 4 [178], and toll like receptor (TLR) 2 and TLR4 [179]. Whether GC regulates
these genes by GRE mediated transcription, translation or cooperation with other
transcription factors is not clear and needs further study.

1.4.3

GR Interactions

Research has shown that GC and its receptor can interact with other hormone receptors and
proteins. This interaction is termed cross-talk and can lead to enhanced or reduced
transcriptional effects, depending on the gene, as well as to chromatin remodeling and
altered accessibility of regulatory elements. For instance, cross-talk between vitamin D
(Vit D) and GC signaling pathways has been shown to improve the effectiveness and anti-
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inflammatory effects of GC [180]. Peripheral blood mononuclear cells (PBMC) from
asthmatic children were treated with the GC dexamethasone (DEX) in the presence or
absence of Vit D. A significant suppression of T-cell proliferation was found with cotreatment, compared to no inhibition with DEX alone, mimicking a steroid resistant model
[181]. Zhang and colleagues showed that that Vit D receptor (VDR) is recruited to the GRE
site in the MKP-1 promoter and enhances GR binding, inactivating the pro-inflammatory
MAPK cascade [182]. Similarly, synergistic interactions between GR and forkhead box O
(FOXO) have also been shown in muscle RING-finger protein-1 (MuRF1) [183].
Collectively, these data show that cross-talk between GR and other transcription factors,
such as VDR and FOXO may enhance GR-mediated transcription.

1.4.4

Apoptosis Mechanism of Action

All cells will inevitably die through manners such as pyroptosis, autophagy, apoptosis or
conversely, oncosis leading to necrosis. [184, 185]. The two contrasting mechanisms,
apoptosis and necrosis, differ based on the death signal [184]. Necrosis is passive cell
death, uncontrolled and toxic; it is induced by direct damage and energy supply reduction
[186]. A key feature in this process is the disruption of the cell membrane, releasing
cytoplasmic and chemotactic signals [186]. In contrast, apoptosis is an active process,
requiring energy [187]. Apoptosis, or self-induced cell death, features caspase activation,
resulting in plasma membrane blebbing, apoptotic body formation, DNA cleavage and
condensation, and phosphatidylserine expression on the outer membrane [188]. No
inflammatory reaction is produced with apoptosis, as the membrane remains intact and the
constituents of the cell are contained within apoptotic bodies phagocytosed by
macrophages [189]. If caspase and adenosine triphosphate (ATP) availability decrease
during apoptosis, the process of cell death will convert to necrosis [190].
Apoptosis can be induced by extrinsic factors, such as the cell surface death pathway, or
intrinsic causes, initiated by the mitochondria. Cytochrome complex (cyt c) is essential for
mitochondrial respiration, acting as part of the electron transport chain, and when thereby
released, creates dysfunction, and leads to apoptosome complex formation, containing
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apoptotic protease-activating factor 1 (Apaf)-1 that binds and activates pro-caspase 9,
leading to caspase-3 activation [191, 192]. Extrinsic stimuli can bind to receptors, such as
tumor necrosis factor receptor (TNFR), on the surface of the cell, and initiate the cascading
responses that activate caspase and induce apoptosis [193]. Intrinsically, apoptosis is
regulated by the B cell lymphoma (Bcl-2) protein family of pro- and anti-apoptotic factors
that engage or block the development of the pore that would allow cyt c to leak out of the
mitochondria and initiate cell death. Bcl-2 and Bcl2-extra large (Bcl-xL), are anti-apoptotic
members, acting to increase resistance to death stimuli and pro-apoptotic members such
as: Bcl-2-associated X protein (BAX), Bcl-2 homologous antagonist killer (BAK), Bcl-2like protein 11 (BIM), and BCL-2-associated death promoter (BAD) inducing apoptosis
[194]. The activation of CD95 (Fas) or TNFR1 death receptors induces the cleavage of
BH3 interacting-domain death agonist (BID), acting as a ligand that induces BAK and
BAX oligomerization to form the mitochondrial pore leaking cyt c [195-197]. Bcl-2 and
Bcl-xL prevent the oligomerization of BAK and BAX, thereby inhibiting mitochondrial
pore formation, caspase activation, and further, block apoptosis [198]. In contrast, BIM
and BAD displace anti-apoptotic Bcl-2 and Bcl-xL, preventing their inhibition of apoptosis
and allowing for mitochondrial pore formation [198].

1.4.5

GC Induced Apoptosis

GCs are anti-inflammatory, functioning to induce apoptosis of inflammatory cells. This is
mediated through a variety of ways. Chromatin immunoprecipitation-sequencing (ChIPseq), used to detect genome wide binding of a factor to DNA, has identified a GR binding
site in BIM regulatory elements, with GC treatment detectably upregulating BIM and
inducing apoptosis [199, 200]. In human pre-B-cell lines, varying levels of BCL-2 altered
the ability of GC to induce apoptosis, with higher expression resulting in less apoptosis,
further proving the anti-apoptotic effect Bcl-2 has [201]. GC bound to GR induces
activation of phosphatidylinositol-specific phospholipase C (PI-PLC), inducing the
activation of acidic sphingomyelinase (ASMase), and further caspase [202, 203]. The
bound complex can also repress both Ap-1 and IL-2 [204]. Glucocorticoid-induced leucine
zipper (GILZ) transcription is also modulated through GC [205]. In transgenic mice,
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overexpression of GILZ induced apoptosis, as detected through reduced Bcl-xL expression
and elevated caspase-3 activation [206].

1.4.6

GC Resistance and Severe Asthma

Despite being an effective treatment for most, since 1968 it was known that GCs are
ineffective to a small proportion of asthmatics with severe disease and that these patients
place a large financial burden on society [207, 208]. There is evidence that some patients
respond to a higher dose of GC; however, that is not the case for all GC resistant asthmatics
[209]. Numerous studies have been conducted to try and identify markers indicating
resistance to GC treatment. T lymphocytes from both GC resistant and sensitive asthmatics
have been cultured in the GCs methylprednisolone or DEX, and cells from resistant
asthmatics showed less inhibition of proliferation compared to GC sensitive patients [210,
211]. Mechanistically, in peripheral blood T cells from severe uncontrolled asthmatics,
reduced GC binding to GR was observed compared to controlled asthmatics [212].
Furthermore, multiple distinct binding abnormalities were identified in steroid resistant
asthmatics, associated with reduced binding affinity [213]. Deficit in other mechanisms
such as GR nuclear translocation and histone acetylation have been suggested to mediate
GC resistance [214]. Indeed, the expression of GRb, the negative regulator of
immunosuppressive GRa, has been associated with steroid resistance [215-217].
Polymorphisms in the GR gene, such as R477H and G678S mutations have been shown
in-vivo to alter the capacity for ligand binding and transactivation [218]. Although crosstalk between GR and endogenous factors such as other hormone receptors has been shown
[180, 183, 219], whether these interactions play a role in GC resistance in these patients is
not clear.
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1.5 Sex Differences in Asthma
A birth cohort analysis in New Zealand identified male sex as a risk factor for asthma in
children under the age of 14 years, with the prevalence being twice as high compared to
girls [220]. The Tracking Adolescents’ Individual Lives Survey (TRAILS) study found
that at mean age 11.1 years, prevalence rates were equal between sexes; however, by the
age of 16.3, females had significantly higher rates than males [221]. Furthermore, the Isle
of Wright Birth Cohort revealed that male sex is associated with remission of asthma in
adolescence [222]. This may be related to lung development, since it has been shown to
vary based on sex, starting from a very young age. Phosphatidylglcerol, a main component
in pulmonary surfactant, was found earlier in gestation in female neonates than males,
potentially explaining female’s elevated airflow rate and minimal resistance compared to
males [223, 224]. That being said, male lungs have been found to be larger than those of
females in children under 14 years [225]. As a major component of the physiological
differences between males and females, sex hormones have been shown to be involved in
lung development, such as androgens inhibiting versus estrogens stimulating lung
maturation in animal models, as well as lung disease like asthma [226, 227].
In addition to development of asthma, sex also appears to influence the severity of asthma.
A multi-center randomized control trial in New Zealand found that female sex was
associated with future severe exacerbations [228]. A national Canadian study found an
association between asthma and obesity in women [229], and further cluster analyses
identified that the late onset development of asthma in obese women was more often of the
severe phenotype requiring oral corticosteroid [230, 231]. Interestingly, obesity is
characterized by increased adipose tissue that increases the hormones estrogen and leptin
[232], and positive associations have been made between elevated leptin levels and
overweight female asthmatics [233]. Moreover, women are more likely to be diagnosed
with asthma, severe asthma, and to have more frequent exacerbations, hospitalizations and
relapses following treatment [6, 234, 235]. Collectively, these observations have led to the
realization that research focused on understanding sex differences in asthma is greatly
needed.
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1.5.1

Effects of Male Sex Hormones on Type 2 Inflammation

The male sex hormone, testosterone, is believed to have a protective effect against allergic
airway inflammation, as elevated levels in the serum of adult males has been associated
with higher FEV1 [236]. Testosterone has also been shown to decrease IL-4 production in
mouse model [237]. Additionally, castrated mice being given androgens show reduced lung
inflammation [238] and androgen signaling inhibited the differentiation of ILC2
progenitors into ILC2s, further preventing type 2 responses [239]. Indeed, androgensandrogen receptor (AR) signaling reduced both the number ILC2 progenitor cells and the
inflammation the cells mediate [240]. Cephus and colleagues [241] found that
gonadectomized male mice had reduced ILC2 cells within the lung when given the
testosterone derivative, 5a-dihydrotestosterone (DHT), versus control. Interestingly, no
change in ILC2 cell numbers were seen when mice were given estradiol. Additionally,
when stimulated ILC2 cells from female mice were treated with DHT they produced less
IL-5 and -13. Despite studies showing that testosterone suppresses type 2 the inflammation,
there is also evidence indicating that sex differences in asthma are not merely due to low
levels of this hormone in females. For instance in a house dust mite (HDM) model of
asthma, androgen signaling reduced but estrogen signaling increased type 2 allergic
inflammation, suggesting this inflammatory pathway may be differentially regulated in
males and females [242].

1.5.2

Female Sex Hormones and Asthma

In contrast to testosterone, the female sex hormones estrogen and progesterone have been
shown to have pro-inflammatory effects and to be associated with reduced respiratory
function at the times these hormones fluctuate within the menstrual cycle [243, 244]. As
such, the prevalence switch of asthma between sexes with less male and more female cases
around the time of puberty and the commencement of the menstrual cycle suggests that
female sex hormones play a role in the development of asthma in girls and women [221].
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The Menstrual Cycle
The menstrual cycle involves cyclical fluctuations in sex hormones and consists of two
phases: follicular and luteal [245]. The follicular phase occurs at the start of menstruation,
with estradiol levels rising until the luteal phase begins at the start of ovulation [245]. At
this point, estrogen levels gradually decrease and progesterone levels increase until the end
of the menstrual cycle, where they rapidly plummet [245]. The negative effects these
hormone fluctuations have on respiratory function have been shown in a variety of studies.
One assessed pulmonary function before and after exercise, and the reduction in FEV1 from
exercise was significantly greater on day 21 of the subjects’ menstrual cycle, when salivary
progesterone was at its highest concentration, compared to day 5, when it was at its lowest
[243]. Moreover, women experienced more respiratory disturbance during their sleep in
the follicular phase, at the point of high estrogen, compared to the luteal phase [244].
Specifically, the fluctuations in estrogen and progesterone at the end of the luteal phase
have been shown to worsen or exacerbate asthmatic symptoms, a phenotype entitled
premenstrual asthma that affect approximately 40% of asthmatic females [246, 247]. Tan
and colleagues showed that the provocative concentration of methacholine to reduce FEV1
by 20% was reduced by 2.5-fold in asthmatic female adults with well-controlled asthma
during peak estrogen and progesterone levels of their menstrual cycles [248]. Furthermore,
asthmatic women taking oral contraceptives, thereby reducing luteinizing hormonal surges
and progesterone levels, had reduced risk of wheeze, and significantly reduced cyclical
airway reactivity changes compared to those not taking oral contraceptives [249, 250].

Pregnancy
Other times of hormonal variation, such as during pregnancy, have also been associated
with exacerbation of symptoms to the extent that they require medical intervention or
hospitalization in 20% or 6%, respectively, of asthmatic patients [251]. This has been
suggested to be related to the increased serum concentrations of progesterone that
accompanies pregnancy [252]. Additionally, pregnancy has been described as a Th2
phenomenon; the Th2 cytokine, IL-4, produced at the maternal-fetal interface was elevated
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in comparison to the Th1 cytokine, IFN-g, and was associated with more successful
pregnancies [253, 254]. In 1984, a prospective study identified that 35% of women
experienced worsening asthma during their pregnancy [255]. Moreover, approximately
40% of asthmatic pregnant females experienced no change, while 30% had increased
severity of asthmatic symptoms despite bronchodilator therapy [256]. Females with severe
asthma prior to pregnancy have been identified as prime candidates to develop worsening
asthma during pregnancy [251]. Interestingly, severe life threatening asthma has been
reported in a small population of females during the first trimester of their pregnancy, with
dramatic improvements in asthma and airflow obstruction within 24 hours of termination
of the pregnancy [257, 258]. Together, these findings suggest that the increase in female
sex hormones associated with pregnancy may be contributing to increased Th2
inflammation and asthma severity often experienced [253, 255].

Menopause
Menopause is associated with the drop of estrogen and progesterone levels and is
considered protective against asthma if the female has never used hormone replacement
therapy; however, this effect is reversed if hormone replacement therapy has been used
[259]. Specifically, studies show that if a female had never taken external estrogen, the
menopause-induced reduction in hormones was associated with reduced risk of asthma
[259]. However, a positive association between dose of conjugated estrogen, commonly
used to treat menopausal symptoms, and risk of asthma has been reported [259, 260].
Together, these studies suggest that estrogen may also play a role in late onset asthma.

1.5.2.1

Female Sex Hormones and Th2 Inflammation

Estrogen has been shown to induce the production of the Th2 cytokines IL-4, IL-5 and IL13 in a mouse model [261]. In women with peri-menstrual asthma increased serum
estradiol during the luteal phase was associated with increased sputum IL-5 [262]. Another
mouse model found that phytoestrogens promote isotype switching in B cells, producing
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increased allergen-specific IgE [263]. Moreover, in the presence of TNFa, estradiol caused
dendritic cells to mature rapidly, resulting in the increased ability to induce Th2 responses
[264]. Larger quantities of mast cells, as well as higher concentrations of histamine released
by mast cells and basophils, were observed in rats when estrogen levels were at their
highest [265-267]. These quantities were reduced with ovariectomy, indicating estrogen
can also promote mast cell degranulation [267]. An increase in mucus producing goblet
cells has been found when cells from female donors were treated with estradiol [268].
Although all these effects induced by estrogen are characteristic of the Th2 response that
occurs in allergic asthma, little is known regarding whether estrogen mediates these effects
by directly acting on Th2 cells.

1.5.2.2

Female Sex Hormones and Cell Survival

One way that estrogen may influence Th2 cells is through apoptosis. Indeed, Th2 cells
treated with estradiol had elevated surface staining for the anti-apoptotic factor, Bcl-2
[269]. Estrogen signaling has been shown to stimulate cell proliferation in a mouse cell
model and increase the anti-apoptotic protein Bcl-xL [270]. A global gene expression
profiling analysis revealed that in a breast cancer cell line (MCF-7), treatment with
estradiol significantly up-regulated proliferative genes such as growth factors and cell cycle
progression regulators, as well as down-regulated pro-apoptotic, anti-proliferative and
transcriptional regulators such as Ap-1 members [271]. Additional gene profiling studies
have shown that estrogen works synergistically with NFkB, a pro-survival transcription
factor, to upregulate anti-apoptotic genes such as cellular inhibitor of apoptosis (cIAP) 2
[272]. Since an important aspect of the anti-inflammatory capacity of GC is induction of
apoptosis, these studies suggest that estrogen may reduce Th2 cell sensitivity to GC and in
this way play a role in asthma severity.
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1.5.3

Estrogen Receptors and Signaling Pathways

The term estrogen refers to a group of hormones: estrone (E1), estradiol (17b-estradiol;
E2), estriol (16-hydroxyestradiol; E3), and estretrol (15a-hydroxyestriol; E4). E2 is
produced by the ovaries and is the most predominant estrogen in the human body during
the reproductive years; however, all estrogens are produced at some point within the life
of a female [273]. During pregnancy, E3, produced by the placenta, is the major estrogen
[274]; however, after menopause, E1, derived from androgen conversions, is the largest
estrogen in the female body [273]. E4 is synthesized by the liver of the fetus during
pregnancy, and circulates through the placenta to the mother [275].
All four estrogens are capable of binding to nuclear and membrane receptors [276]. The
estrogen receptor (ER) was first discovered in 1958 by Jensen and colleagues, and since
then three ERs have been characterized: ERa, ERb, and most recently G Protein-Coupled
ER (GPER)1 [277-279]. ERa and ERb are nuclear receptors and ligand-activation
transcription factors encoded by the gene ESR1 and ESR2 on chromosome 6 and 14,
respectively [280, 281]. The membrane receptor, GPER1 gene is encoded on chromosome
7 [282].
Despite being completely separate genes, ERa and ERb signal similarly through
mechanisms such as the classical direct genomic pathway. Estrogen diffuses through the
plasma membrane and binds to ERa and/or ERb, inducing a conformational change and
either homo- or hetero-dimerization [283]. The complex then translocates into the nucleus
where it binds to estrogen response elements (EREs) and regulatory elements within
promoters [284]. It is thought that ERa interactions with EREs typically enhance gene
expression, whereas ERb repress expression at AP1 sites [285]. That being said,
approximately one third of genes regulated by ERs do not have ERE sequences [286].
Therefore, they act through indirect genomic signaling or cross-talk/protein-protein
interactions with other response elements and transcription factors like AP-1[219, 286,
287]. Additionally, ER can act on specificity protein (Sp)-1, enhancing the binding of the
protein to its site [288]. Lastly, non-genomic estrogen signaling occurs through the
membrane-associated GPER1, indirectly influencing gene expression through activating
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signal transduction pathways that on act downstream transcription factors [279]. For
example, estrogen binding to GPER1 rapidly activates extracellular signal-regulated
kinases (ERKs) [289].
Both ERa and ERb are known to be expressed in human lung tissue [290]. Furthermore, it
is thought that ERa is more relevant than ERb in inducing allergic inflammation. On the
genomic level, SNPs in the ESR1 gene have been associated with decreased FEV1 in
asthmatics [291]. On a cellular level, both eosinophils and mast cells express ERa and not
ERb, and mice challenged with an allergen and then treated with ERa antagonists had
reduced eosinophils as well as Th2 cytokines [261, 292, 293]. ERb has also been found to
have an anti-inflammatory role in asthma; airway smooth muscle hyperplasia,
characteristic of allergic asthma, depends on stimulation by platelet-derived growth factor
for proliferation, and an ERb agonist was shown to suppress this proliferation [294].
Further, ERb signaling has been associated with increased apoptosis, as well as an increase
in pro-apoptotic BAX expression [270]. A mouse model demonstrated that E2 treatment
reduced tidal volume and airflow rate, increased eosinophils, and induced alveolar and
muscular layer destruction in asthmatic mice compared to control asthmatic and nonasthmatic groups. The group receiving E2 as well as a selective ERa antagonist resulted in
no difference in any of the measurements compared to control asthmatic mice, indicating
the pro-inflammatory effect was primarily through ERa [295].

1.5.4

Cross-talk between Estrogen and Glucocorticosteroid

Estrogen receptors participate in cross-talk, interacting with other proteins and steroids to
modulate gene transcription through competition or cooperation (Fig. 1.3). Importantly for
this thesis, crosstalk been ER and GR occurs, and has been suggested to play a role in the
increased disease severity and reduced sensitivity to treatment many asthmatic women
experience [296].
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Competition
In certain circumstances, GR and ER can interact in a competitive manner and have
opposing effects on inflammation (Fig. 1.3B). Breast cancer cell lines treated with estradiol
had downregulated GR expression and responses to GC [297]. More so, an inverse
relationship between ER and GR expression has been identified [298]. Estradiol induces
protein phosphatase 5 (PP5), which inhibits GR phosphorylation and further prevents GCinduced transcription of anti-inflammatory MKP-1 [299, 300]. This is an example of an indirect interaction between the two steroid receptors. The synthetic GC DEX inhibits
proliferation of a human breast cancer cell line, whereas E2 stimulates proliferation [301].
Interestingly, the effects are opposite in bone; GC induces resorption whereas E2 inhibits
resorption [302, 303]. It has been shown that ER expression can inhibit the activation of
GR, and vice versa due to the competition for functionally limiting transcription factors
[304]. A ChIP study used to identify protein interactions with DNA, discovered that GR
occupied multiple EREs when treated with both DEX and E2; however, if DEX or E2
treatment was administered alone, minimal GR binding at the EREs occurred [305].
Additionally, the GR recruitment was associated with ERa displacement, but also required
ERa, FOXA1 and AP1 binding, thus uncovering a mechanism for GC inhibition of ERa
activation [305]. Yang and colleges found that GR repressed ERa activated transcription
through binding to EREs already occupied by ERa, halting the effective activation [306].
On the other hand, estradiol has been shown to inhibit GILZ expression in uterine epithelial
cells through reduced binding of GR to a GRE within the GILZ promoter in the presence
of ERa [307]. These studies highlight that in some circumstances GR and ER can act in a
competitive manner, with ER inhibiting GR mediated transcription.

Cooperation
GR and ER cross-talk has also been shown to be cooperative, increasing the accessibility
to regulatory elements (Fig. 1.3C). The use of indirect genomic estrogen signaling can
allow for transcription factors, such as Sp-1, to have enhanced binding at GC-rich sites
[308]. These steroids can work together in a rat model of lung inflammation since the ERa
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antagonist reversed the anti-inflammatory effect of DEX [309]. Molecularly, Hager and
colleagues discovered that when both estradiol and GC are present and their respective
receptors are activated, receptor binding is redistributed [310]. Overlapping ER and GR
binding sites were found in cells treated with E2 or DEX alone compared to treatment with
both DEX and E2, respectively, as well as unique binding sites specific to E2, DEX, and
E2 and DEX co-treatment [310]. Nine major binding clusters were identified between ER
and GR combined, the majority representing regulatory regions; however, GR and ER
individual binding clusters were found and activated by their own receptor, and for some,
activated by the other receptor, indicating assisted-loading regions [310]. Moreover,
DNase I digestions showed that activation of the receptor promoter by the opposite receptor
induced unique chromatin structural changes, facilitating this new binding [310].
Furthermore, a GR ChIP-seq identified GR binding regions, and that co-treatment with
DEX and E2 increased GR enrichment at sites through chromatin remodeling [311]. Dual
receptor activation also resulted in GR showing increased binding at GR, ER, FOXO and
AP1 regulatory elements [311]. Cumulatively, the research suggests that within some cell
types ER may act to stabilize or increase accessibility, enhancing GR binding.
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Figure 1.3: Glucocorticoid and Estrogen Cross-talk
Unperturbed, the GC-GR homodimer complex binds to the GRE (A). In the presence of
E2, cross-talk between the GC and E2 can occur and result in B) the inhibition of GC
binding to GRE, or C) increased stability and accessibility allowing for more binding of
GC to the GRE. Abbreviations are as follows: estradiol, E2; glucocorticoid, GC;
glucocorticoid receptor, GR; glucocorticoid response element, GRE. Created with
BioRender.com.
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1.6 Rationale
Despite the abundance of evidence revealing sex differences in the development and
severity of asthma [6, 312], the pathobiology driving these differences is still not well
understood. In a study performed by my colleagues, significantly higher levels of
circulating Th2 cells were found in women compared to men with severe asthma (App.
1.1). This may be due to differential response to GC, since the level of Th2 cells was
positively correlated with daily dose of inhaled GC in women, but not men (App. 1.2).
There are two main mechanisms by which GCs reduce inflammation - suppression of
cytokine production and induction of apoptosis [134]. The Cameron laboratory recently
demonstrated that estrogen, in concert with GC, increases the level of CRTh2 mRNA and
protein (App. 1.3) in primary human Th2 cells. This could suggest that Th2 cell sensitivity
to PGD2 and its ability to inhibit apoptosis differs between men and women.
The finding that GC and estrogen increase CRTh2 expression is intriguing, but whether
this increase occurs at the level of transcriptional activation is not known. This seems
possible since the CRTh2 promoter contains a number of GREs and estradiol has been
shown to cooperate with GR to enhance gene expression [311, 313, 314]. Transcriptional
activation of CRTh2 may also be influenced by genetic variation, since the CRTh2
promoter SNP, CRTh2-6388G>A, was previously shown to associate with asthma risk
[102] and increased CRTh2 expression [103].
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1.7 Hypothesis and Objectives
1.7.1

Hypothesis

Estrogen inhibits glucocorticoid-induced apoptosis by increasing CRTh2 expression and
this effect occurs at the level of CRTh2 promoter activation.

1.7.2

Objectives

Objective 1: To determine how estrogen receptor signaling influences GC-induced
apoptosis
PGD2 activation of CRTh2 inhibits Th2 cell apoptosis [68] and so whether an increase in
CRTh2 expression, mediated by GC and estrogen, enhances Th2 cell survival was
examined.
Sub-hypothesis: Estrogen signaling reduces GC-induced apoptosis by increasing
expression of CRTh2 and sensitivity to PGD2.

Objective 2: To determine whether GC and estrogen receptor signaling activate the CRTh2
promoter and if this response is altered by a CRTh2 promoter SNP
Mapping of putative transcription factor binding sites within CRTh2 revealed a number of
GRE sites, including one 6 bp away from the CRTh2-6388G>A SNP. Estradiol can enhance
GR binding [311, 313, 314] and so whether concomitant exposure to these hormones would
increase transcriptional activation of CRTh2 in an allele specific manner was investigated.
Sub-hypothesis: GC and estrogen signaling induce CRTh2 promoter activation and the
magnitude of this effect differs based on the CRTh2-6388G>A SNP.
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Chapter 2

2

Materials and Methods

2.1 Cell Culture
2.1.1

In Vitro Differentiated Primary Th2 Cells

A number of attempts were made to differentiate Th2 cells for this study. Blood was drawn
from healthy non-asthmatic donors (Western University Ethics Review Board; approval
number 106770) and peripheral blood mononuclear cells (PBMC)s were obtained by
centrifuging blood over Ficoll Histopaque PLUS (GE Healthcare, Sweden) and isolating
the mononuclear cells. The naïve CD4+ T cell Isolation Kit II (Miltenyi Biotech, CA, USA)
was used to obtain untouched naïve CD4+ T cells. With this kit all cell types other than
naïve CD4+ T cells are labeled with biotin-conjugated antibodies/microbeads and are
retained within the MACs column. Cells were activated for 3 days on plate-bound
antibodies (anti-) to CD3e (1 µg/mL; Clone UCHT1, R&D Systems Bio-Techne, MN,
USA) and CD28 (1 µg/mL; Clone 37407, R&D Systems Bio-Techne, MN, USA) in XVIVO 15 medium (Lonza, USA) with 10% Premium Fetal Bovine Serum (FBS) (Wisent,
QC, Canada) and Penicillin, Streptomycin, and L-glutamine (1%, Gibco, Canada), as well
as Th2 polarizing conditions: recombinant human (rh) IL-2 (5 ng/mL; R&D Systems BioTechne, MN, USA), rhIL-4 (10-20 ng/mL; R&D Systems Bio-Techne, MN, USA),
antibodies against IFN-g (1 µg/mL; polyclonal, R&D Systems Bio-Techne), and IL-12 (1
µg/mL; Clone C8.6; Invitrogen, CA, USA). The cells were then reseeded in fresh media
and polarizing conditions in the absence of anti-CD3/CD28 for 4 days. On day 14, cells
were incubated with magnetic beads conjugated with antibody against CRTh2, loaded onto
MACS columns and cells expressing CRTh2 were obtained using the CRTh2+ cell
selection kit (Miltenyi Biotech, CA, USA).
Despite these attempts to generate newly differentiated Th2 cells, the studies within this
thesis were carried out with Th2 cells previously differentiated by a former laboratory
member. This Th2 cell line was generated by isolating PBMCs from blood donated by a
healthy, non-asthmatic female (University of Alberta Ethics Review Board; approval
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number PRO1784) and centrifugation over Ficoll Histopaque PLUS (GE Healthcare,
Sweden). The starter population was total CD4+ T cells using a CD4+ T cell Isolation Kit
II (Miltenyi Biotech, CA, USA). These cells were cultured in identical differentiation
conditions, except that the X-VIVO 15 media was supplemented with 10% FBS from
HyClone and cells were differentiated for 14 days prior to CRTh2 isolation (CRTh2+ cell
selection kit, Miltenyi Biotech, CA, USA). These CD4+CRTh2+ T cells (i.e. Th2 cells)
were expanded by activation on plate-bound anti-CD3/CD28 and multiple vials frozen
down. For this thesis, these Th2 cells were thawed and re-cultured in X-VIVO 15 (Lonza,
MD, USA), supplemented with 10% Premium FBS (Wisent, QC, Canada) and the
antibiotics Penicillin, Streptomycin, and L-glutamine (1X; Gibco, ON, Canada) and
cultured as above on cycles of activation (plate-bound anti-CD3/CD28, 1 µg/mL; 3 days)
and proliferation (rhIL-2, 5 ng/mL; 4 days) at a concentration of 2.0´106 cells/mL and
incubated at 37°C, in 85% humidity and 5% carbon dioxide (CO2).

2.1.2

CCRF-CEM Cells

CCRF-CEM [CCRF CEM] (ATCC ® CCL-119 TM) cells were purchased from American
Type Culture Collection (Manassas, VA, USA) and cultured in RPMI-1640 medium
(Sigma Aldrich, ON, Canada) supplemented with 10% Performance FBS (Wisent, QC,
Canada) and the antibiotics Penicillin, Streptomycin, and L-glutamine (1X; Gibco, ON,
Canada). The cells were seeded every second day at 0.2´106 cells/mL and maintained at
37°C, 5% CO2, and 85% humidity. CCRF-CEM cells are an immortalized CD4+ T
lymphoblastic cell line, derived from a 4-year-old Caucasian female.

2.2 GC and Estrogen Exposure of Th2 Cells
Experiments with primary Th2 cells (1.3´106 cells/mL) were performed after the
proliferation phase in media supplemented with rhIL-2 (1.25 ng/mL). Experiments with
CCRF-CEM cells (0.2´106 cells/mL) were performed on the day after split, during
logarithmic growth. Cells were treated with varying concentrations and combinations of
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dexamethasone (0.01-1.0 µM; Sigma Aldrich, ON, Canada), Propylpyrazole-triol (1.0 µM
PPT; Tochris, ON, Canada), 17 b-estradiol (0.1 µM; Sigma Aldrich, ON, Canada), and
Prostaglandin D2 (1.0 µL; Caymen Chemicals, Czech Republic), all reconstituted in
ethanol. Vehicle control was 0.03% ethanol.

2.3 Flow Cytometry
2.3.1

CRTh2 Surface Levels

Surface level of CRTh2 on primary Th2 cells and CCRF-CEM cells was demonstrated
using a similar staining protocol. Cells were harvested 24 hours following treatment,
washed with phosphate buffered saline (PBS) fluorescence-activated cell sorting (FACS)
(3% FBS, 0.5% bovine serum albumin, 1% sodium azide), centrifuged (900 rpm for 10
minutes at 4°C), then re-suspended in fresh PBS FACS and re-washed. Cells were blocked
with rat IgG antibody (3 mg/mL; Invitrogen, CA, USA) in PBS FACS (0.5´106 cells/mL)
for 45 minutes at room temperature. Following this step, anti-CRTh2 AlexaFluor 647
antibody (75 ng/mL; clone BM16; Rat IgG2a, BioLegend, CA, USA) or rat IgG2a κ
Alexa647 control (75 ng/mL; clone RTK2758; BioLegend, CA, USA) was incubated with
the cells (30 minutes, at 4°C). After two washes with PBS FACS, cells were fixed with 4%
paraformaldehyde. Data was obtained using the LSR II Flow Cytometer (BD, CA, USA)
with FACSDiva Software (BD, CA, USA) at the London Regional Flow Cytometer
Facility. The data was then analyzed using the FlowJo (Treestar, Ashland, USA) computer
application depicting total percent of cells positive for CRTh2.

2.3.2

Apoptosis

Annexin V and 7-Aminoactinomycin D
To assess apoptosis and cell death, cells were stained with Annexin V and 7Aminoactinomycin D (7-AAD). Annexin V stains phosphatidylserines translocated from
the inner membrane to the outer membrane (characteristic of apoptosis) and 7-AAD stains
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DNA and thereby identifies cells with compromised plasma membranes. For these
experiments, Th2 cells and CCRF-CEM cells were treated similarly with various
concentrations of dexamethasone and estrogen receptor agonists for 48 hours. After this
exposure, cells were washed with PBS FACS (0.5´106/tube), centrifuged (900 rpm for 10
minutes at 4°C), and re-suspended in 100 µL of Annexin V binding buffer (10mM HEPES,
140mM NaOH, 2.5mM CaCl2, and 15.2 mL of H2O) before staining with Annexin V-Alexa
Fluor 647 reagent (1 µL; BioLegend, CA, USA) and 7-AAD Viability Staining Solution (5
µL; BioLegend, CA, USA). The tubes were incubated at room temperature for 15 minutes
in the dark before diluting with Annexin V binding buffer (400 µL). At the London
Regional Flow cytometer facility, using the data obtained through the LSR II Flow
Cytometer (BD, CA, USA) and FACSDiva Software (BD, CA, USA), total percent of
Annexin V+ and 7-AAD + cells was acquired and presented through FlowJo (Treestar,
Ashland, USA).

Fluorochrome-Labeled Inhibitor of Caspases Assay
To confirm apoptosis, caspase activity was assessed using a fluorochrome-labeled inhibitor
of caspases assay (FLICA). Primary Th2 cells (0.5´106 cells/condition) treated with
dexamethasone (0.1-1.0 µM) and/or PPT (1.0 µM) for 48 hours were harvested and washed
in PBS FACS and then re-suspended in PBS FACS and 30X FAM-FLICA poly caspase
inhibitor reagent (ImmunoChemistry Technologies, LLC; MN USA). Following an
incubation period (30 min at room temperature) in absence of light, cells were washed
twice with 1X Apoptosis Wash Buffer (ImmunoChemistry Technologies, LLC; MN USA)
and centrifuged (1000 rpm for 5 minutes at room temperature). The cells were then resuspended in 400 µL 1X Apoptosis Wash buffer, and 2 µL Propidium Iodide (PI) to
exclude the dead cells, before data was acquired on the BD LSR II Flow Cytometer (BD,
CA, USA) and analyzed on FlowJo (Treestar, Ashland, USA).
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2.4 Transcriptional Activity
2.4.1

Plasmid Generation

Reporter constructs of varying lengths of the CRTh2 promoter were previously generated
by my colleagues. Nomenclature is relative to the translation start site (rATG) using human
genome build GRCh8/hg38. CRTh2pro-4513/Luc contains the 1836 base pairs (bp)
upstream of the transcription start site and was designed to study core transcriptional
activation of CRTh2. Longer CRTh2 promoter constructs (-7013, rATG) were generated to
study the CRTh2 SNP rs533116G>A located at -6388 and were named CRTh2pro6388G/Luc and CRTh2pro-6388A/Luc. CRTh2 promoter fragments were cloned into
pGL3-Basic reporter vector (Promega, Madison, WI) using KpnI and NheI sites, and subcloned into DH5a E. coli.

2.4.2

Plasmid Growth

These CRTh2 promoter constructs are high copy plasmids and were grown for 8 hours by
inoculating 5 mL of Lysogeny broth (LB) supplemented with Ampicillin (100 µg/mL),
agitated (300 rpm at 37°C), before being transferred into 100 mL of fresh LB (100 µg/mL
Ampicillin) for 16 hours (300 rpm at 37°C). An EndoFree Plasmid Maxi Kit (Qiagen,
Netherlands) was used to purify plasmids and DNA was eluted in 100 µL of endotoxinfree Tris EDTA buffer. The yield and purity were assessed using the Epoch Microplate
Spectrophotometer (Biotek, VT, USA) and the software Gen 5 Analysis Software (Biotek,
VT, USA) prior to dilution to 1 µg/µL.
Single and double digests (1 µg DNA) were performed with Kpn I and/or NheI in
NEBufferTM 1.1 (1X, New England Biolabs, ON, Canada), incubated at 37°C for 1 hour.
Digests were electrophoresed on a 1% agarose gel to the separate the fragments based on
size and confirm the integrity of each plasmid.
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2.4.3

Transient Transfection by Electroporation

Transcriptional activity of CRTh2 was determined by transiently transfecting the CRTh2
promoter constructs into CCRF-CEM cells by electroporation. Transfection efficiency was
assessed by co-transfection of thymidine kinase promoter-Renilla luciferase plasmid (pRLTK; 11.5 ng) and CRTh2pro/Luc (20 µg or molar equivalent) with 10-minute incubations
on ice for each plasmid. A square wave electroporator (ECM 830, Harvard Apparatus, MA,
USA) was used with settings of 1 pulse 50 msec at 240 V. Cells (5.0´106 cells/condition)
were then treated with dexamethasone (0.01-0.1 µM) in the presence or absence of PPT
(1-10 µM) for 22 hours prior to being harvested and lysed in 250 µL of passive lysis buffer
(1X PLB, Promega, WI, USA) and frozen.

2.4.4

Dual-Luciferase Promoter Assay

Frozen lysate was thawed and 10 µL of each sample was incubated with 50 µl of the Firefly
luciferase substrate, luciferin, and repeatedly mixed before reading on the GloMax 20/20
Luminometer (Promega, WI, USA) with an integration time of 10 seconds. Renilla
luciferase substrate, coelenterazine, (50 µL) was then added, mixed and read on the
Luminometer. Total lysate protein was measured by standard curve generated using a
Pierce BCA Protein Assay Kit (ThermoFisher Scientific, IL, USA). Results were expressed
as relative luciferase units (RLU), normalized for transfection efficiency and protein
concentrations using the following formula:
RLU = Firefly Luciferase Count ×

Mean Baseline Renilla Mean Protein
×
Renilla Count
Protein Count

38

2.5 Statistical Analysis
Results are presented as mean ± standard error of mean (SEM), with the exception of results
with only two experiments which were presented as deviation of individual data from the
mean. One-way analysis of variance (ANOVA) or one-way repeated measures ANOVA
were performed to compare independent and related groups, respectively. The one-way
repeated measures ANOVA, alternatively referred as a randomized block design ANOVA,
is similar to a paired t-test for multiple comparisons [315]. This statistical test accounts for
day-to-day variation of the cell line and has been used by others [316]. Each experimental
run, referred to as a block [315], had multiple measurements made in parallel, rationalizing
the choice of statistical test. Multiple comparison analyses were performed using either
Tukey’s test, to calculate the confidence interval and identify statistical differences
between means that are larger than the standard error, and/or Holm-Sidak test, to accept or
reject the null hypotheses. A p-value less than 0.05 was indicative of a significant
difference. Significance was assessed with SigmaPlot (Version 12.5; Systat Software Inc,
CA, USA).
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Chapter 3

3

Results

3.1 Th2 Cell Differentiation
The Cameron laboratory has a long history of differentiating human primary Th2 cells
[317, 318] and so I began my project with the goal of creating newly differentiated primary
Th2 cell lines. Despite a number of attempts (n=9), viable Th2 cells could not be generated.
Naïve CD4+ T cells were cultured in IL-2, IL-4, antibody against IFNg and IL-12 and
alternating cycles of activation (3 days on or 4 days off plates coated with antibody against
CD3 and CD28). On day 14, if the amount of cells and predicted yield was feasible,
CRTh2+ cells were isolated and the enriched Th2 cells cultured in similar conditions,
without IL-4 or neutralizing antibody. This protocol was previously shown to result in a
doubling of cells (i.e., growth rate = 2) [317, 318], however, only a few of the lines I
differentiated maintained that growth rate and most cell lines died prior to day 14 (Fig.
3.1). Cells from donors 1 through 6 had reduced/negligible growth prior to isolating cells
expressing CRTh2. Despite maintaining viability, there were not enough Th2 cells from
donor 9 to complete a CRTh2 isolation with a suitable yield. Two sets of Th2 cells from
donor 7 and 8 maintained steady growth until day 14, when Th2 cells were isolated.
Unfortunately, these Th2 cells failed to expand following isolation. As such, experiments
within this thesis were performed with a Th2 line differentiated by Emily MacLean Scott
(Dr. Cameron’s former M.Sc. student, University of Alberta) [318] or with the
immortalized CD4+ T cell line CCRF-CEM, an immortalized cell line previously shown to
have features similar to Th2 cells [319].
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Figure 3.1: Growth of CD4+ T Cells Culture in Th2 Differentiating Conditions
Primary naïve CD4+ T cell were isolated from healthy donors (D) and cultured on
alternating cycles of activation (3 days on plates coated with aCD3 and aCD28) followed
by proliferation (IL-2, 4 days). Cell counts were performed using a microscopic
hemocytometer and extrapolated to determine cell population quantity on days of reseeding
(alternating on and off aCD3/28 coated plates). Isolation of CRTh2+ cells was performed
on day 14 of culture (indicated by dotted line), if the number of cells was predicted to
provide a feasible yield of Th2 cells. n=9.
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3.2 ERa Agonist Dampens GC-Induced Apoptosis of Primary Th2
Cells
My colleagues have previously shown that treating primary Th2 cells with the synthetic
GC dexamethasone (DEX) induces cell death through apoptosis [320]. These experiments
were performed by quantifying the proportion of intact cells exhibiting positive staining
for phosphatidylserine residues, which flip from the inner to the outer leaflet of the plasma
membrane during apoptosis [188]. My research question centered on whether estrogen
receptor signaling could influence GC-induced apoptosis. To test this, Th2 cells were
cultured with DEX (0.1 – 1.0 µM) in the presence or absence of a selective ERa agonist
(PPT, 1.0 µM) for 48 hours and cells stained with fluorochrome-conjugated Annexin V.
This approach identifies phosphatidylserines on the outer and inner plasma membrane that
occurs during the early stages of apoptosis and late stages of cell death, respectively. To
exclude necrotic cells with ruptured plasma membranes, the cells were also stained with
the nucleic acid stain, 7-AAD conjugated to a fluorophore. Positive staining was assessed
by flow cytometry and the proportion of Annexin V+/7-AAD- cells were reported as
apoptotic Th2 cells, gating as shown in Appendix 3.1.
Similar to previous reports [319, 320], I found that DEX treatment induced Th2 cell
apoptosis. Phosphatidylserine levels measured by Annexin positivity were significantly
increased with all DEX treatments alone, and significantly lower with PPT co-treatment
(Fig. 3.2A). Approximately 10% of the cells stained positive for Annexin V when treated
with vehicle and this was similar with PPT alone. Treatment with DEX induced apoptosis
to approximately 44%, however, cells co-treated with PPT showed a reduction in Annexin
V+ cells to approximately 38%, on average 12% lower (6.7-17.9% dependent on DEX
concentration) (P<0.05; Fig. 3.2A). A limiting factor of this analysis is the lack of
specificity differentiating apoptotic and necrotic cells; therefore, apoptosis levels were also
assessed by identifying Annexin V+ cells and excluding 7-AAD necrotic cells (Annexin
V+/7-AAD) (Fig. 3.2B). Th2 cells treated with DEX had an increase in apoptosis from
~10% of non-treated cells to 30% (P<0.05; Fig. 3.2B). A reduction in apoptosis in DEX
and PPT co-treated cells was apparent at all concentrations of DEX by a mean of 10% (6.113.3%) (P<0.05; Fig. 3.2B).
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Since this is an indirect method of measuring apoptosis, these findings were confirmed by
staining with a fluorochrome-labeled inhibitor of caspases (FLICA). This reagent binds
and inhibits active caspase 1, 3, 4, 5, 6, 7, 8 and 9, the enzyme responsible for apoptosis
[203]. The inhibitor is conjugated to a fluorophore detectable by flow cytometry. The
conformational FLICA stain proved that DEX treatment significantly increased the
quantity of activated caspases and that co-treatment of 0.1 µM DEX and 1.0 µM PPT
showed significantly less caspase activation (Fig. 3.2C). Control and PPT alone had ~5%
active caspase positive cells, while DEX treatment induced approximately 30% that was
reduced to 12% with co-treatment with 1.0 µM PPT, a 48.3% reduction (P<0.05; Fig.
3.2C). In all analyses, PPT alone had no effect on caspase activation, suggesting the
reduction was due to the combination of GC and ERa.
Analysis of FLICA+ cells and Annexin V+/7-AAD- showed comparable results. Th2 cells
treated with DEX were 40% Annexin V+ (Fig. 3.2A), however, both Annexin V+/7-AADand FLICA+ identified ~30% of the cells were apoptotic (Fig. 3.2B/C). These results
suggest that the Annexin V+/7-AAD- method has similar sensitivity as FLICA for detecting
apoptosis.
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Figure 3.2: The Effect of PPT on DEX-Induced Apoptosis in Primary Th2 Cells
Measurement of apoptotic primary Th2 cells by flow cytometry after 48 hour exposure to
DEX in the presence and absence of PPT. Percentage of Th2 cells that were Annexin V+
(A; n=11) or Annexin V positive and 7-AAD negative (B; n=11). Percentage of Th2 cells
that were FLICA positive as assessed by flow cytometry under the same conditions was
also assessed (C) (n=5). All data represents mean ± SEM. One-way repeated measures
ANOVA were used to determine statistical differences. Asterisk (*) represent significance
(P<0.05) vs control, number sign (#) represents statistical differences between conditions,
and ns represents condition not significant vs control.
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3.3 The Effect of E2 on GC-Induced Apoptosis is Similar to that
of ERa Agonist in Primary Th2 Cells
My hypothesis was that estrogen reduces GC-induced apoptosis by increasing CRTh2
levels and sensitivity to PGD2-mediated inhibition of apoptosis. Therefore, I next set out
to confirm that the influence of the physiologically relevant sex hormone, estradiol (E2),
was similar to the effect of the selective ERa agonist (PPT). Preliminary experiments were
performed to determine the concentration of estradiol that cooperates best with DEX to
induce CRTh2 levels. Primary Th2 cells were treated with DEX in the presence and
absence of E2 for 24 hours and then stained for CRTh2 by flow cytometry (Fig. 3.3).
Control Th2 cells were approximately 30% CRTh2 positive, and this was not significantly
changed with treatment with either DEX or E2 alone. Interestingly, co-treatment with
either 0.1 or 1.0 µM E2 and DEX increased surface CRTh2 levels to approximately 60%,
a 2 fold increase (P<0.05; Fig. 3.3A). Normalization to control to eliminate variability
within experiments indicated similar findings (Fig. 3.3B). Co-treatment with 0.1 µM DEX
and 0.1 µM E2 increased surface levels by over 1.5 fold, and DEX with the higher 1.0 µM
E2 had increased CRTh2 surface levels just under 1.5 fold. Based on these findings, 0.1
µM E2 was used for apoptosis assays.
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Figure 3.3: CRTh2 Surface Levels in Primary Th2 Cells in Response to E2
Primary Th2 were treated for 24 hours with DEX and/or E2. CRTh2 surface staining was
then performed and assessed by flow cytometry. The proportion of the entire population
that is CRTh2 positive (A) and proportion normalized to control (B) was identified and
represented as mean ± SEM. Statistical differences were determined through one-way
repeated measures ANOVA. Asterisk (*) represent significance (P<0.05) vs control. n=6.
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Primary Th2 cells were then treated with DEX (0.1-1.0 µM) in the presence and absence
of E2 (0.1 µM) for 48 hours. Cells were stained and the proportion of Annexin V+/7-AADcells, identifying apoptotic cells, was assessed by flow cytometry. The outcome of this
experiment was that E2 treatment alone had no effect on apoptosis; 15% of the Th2 cells
were Annexin V+/7-AAD- with either vehicle control or E2 treatment. DEX treatment at
all concentrations resulted in approximately 35% apoptotic cells and co-treatment with 0.1
µM DEX and 0.1 µM E2 significantly reduced the apoptosis achieved by DEX alone by
38.2 % to 20% (P<0.05; Fig. 3.4).

Figure 3.4: Apoptosis of Primary Th2 Cells in Response to E2 and DEX
Primary Th2 cells were treated with DEX and E2 for 48 hours to determine apoptosis and
cell death using flow cytometry. Percentage of Annexin V positive 7-AAD negative cells
were assessed. Data were represented as mean ± SEM. Statistical differences were
determined by using one way ANOVA. Asterisk (*) represents statistical differences
(P<0.001) vs control, and number sign (#) represents statistical differences (P<0.05)
between conditions. n=4.
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3.4 Identifying the Mechanism behind Reduced Apoptosis with
GC and ERa Agonist Co-treatment
ERa Selective Agonist, but not E2, increases CRTh2 Surface Levels in CCRFCEM Cells
CRTh2 surface levels were found to be elevated in primary Th2 cells after exposure to a
combination of the E2 and DEX (Fig. 3.3). We required more Th2 cells to continue these
experiments and so differentiation of new primary Th2 cell lines was attempted, but
without success (Fig. 3.1). Therefore, experiments were transition to the immortalized
lymphoblast T cell line, CCRF-CEM cells. The effects of DEX and E2 on CRTh2 surface
levels were first examined, but were dissimilar to primary Th2 cells (Fig. 3.3). While
control cells were ~60% CRTh2 positive, following 24 hour treatment with DEX (0.1-0.01
µM) and/or E2 (0.01-10 µM), no significant increases were found (Fig. 3.5). Although
treatment of cells with 10 µM E2 did result in more CRTh2 positive cells compared to
baseline levels (Fig. 3.5C), normalization of results to vehicle eliminated this effect (Fig.
3.5D).
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Figure 3.5: The Effect of DEX and E2 on CRTh2 Surface Levels in CCRF-CEM
Cells
CCRF-CEM cells were treated with DEX and/or E2 for 24 hours. CRTh2 surface level was
measured by flow cytometric analysis. DEX concentrations of 0.01 µM (A/B) and 0.1 µM
(C/D) were co-treated with varying concentrations of E2 (0.01-10 µM). Data is represented
as mean ± SEM of percentage of cell population expressing CRTh2 (A/C) and data
normalized to control (B/D). Significance was determined through one-way repeated
measures ANOVA. Asterisk (*) represents significance versus control. n=7.
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The Cameron laboratory had previously shown that co-treatment with GC and a selective
agonist for ERa (PPT) also increased CRTh2 levels on primary Th2 cells [1]. Therefore, I
concurrently performed a dose response to determine if directly activating ERa with PPT
induces CRTh2 surface levels on CCRF-CEM. These experiments showed that cells treated
with DEX (0.01 or 0.1 µM) and/or PPT (1 or 10 µM) for 24 hours did exhibit increased
surface levels of CRTh2. The total percentage of CRTh2 positive cells (Fig. 3.6A/C) was
found to be significantly increased compared to vehicle control. Normalization to vehicle
control further demonstrated these same findings; with significant increases in surface
levels observed present in all DEX and PPT co-treatments (Fig. 3.6B/D).
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Figure 3.6: CRTh2 Surface Levels in Response to DEX and PPT Co-Treatment in
CCRF-CEM Cells
CRTh2 surface levels on CCRF-CEM cells following treatment with DEX and/or PPT for
24 hours was determined by flow cytometry. DEX concentrations of 0.1 µM (A/B; n=11)
and 0.01 µM (C/D; n=5) were used in combination with 1µM and 10 µM PPT. The data
represents mean ± SEM of percentage of the entire cell population expressing CRTh2
(A/C), or the percentage normalized to control (B/D). Statistical differences were measured
using one-way repeated measures ANOVA. Asterisks (* and ***) represent significance
(P<0.05 and P<0.001, respectively) vs control, and number sign (#) represents significance
between conditions.
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CRTh2 Activation by PGD2 does not Reduce Apoptosis in CCRF-CEM Cells
Since increased CRTh2 surface levels were observed following DEX and PPT co-treatment
in CCRF-CEM cells and the activation of CRTh2 has been shown to mediate anti-apoptotic
effects [8], I next examined if this was the mechanism behind the reduced apoptosis we
found in primary Th2 cells with this co-treatment. CCRF-CEM cells were treated with
various combinations of DEX (0.1-0.5 µM), PPT (1-10 µM) and PGD2 (0.1-1.0 µM) for
48 hours before being stained for phosphatidylserine and nucleic acid with Annexin V, 7AAD, respectively. Flow cytometric analysis of Annexin V+/7-AAD- cells identified the
proportion undergoing apoptosis. At baseline conditions, 5% of the CCRF-CEM cell
population were apoptotic; treatment with PPT or PGD2 did not alter the proportion of
Annexin V+/7-AAD- cells. DEX (0.1-0.5 µM) induced apoptosis of the CCRF-CEM cells
(~20%), but PPT did not reduce DEX induced apoptosis in CCRF-CEM cells (Fig. 3.7), as
it did in primary Th2 cells (Fig. 3.2). The ligand for CRTh2, PGD2, was added in
combination with DEX to activate the CRTh2 on CCRF-CEM cells (Fig. 3.7). Despite the
study suggesting activation of CRTh2 inhibits apoptosis [8], there was no difference in the
proportion of apoptotic cells in this co-treatment compared to cells treated with DEX alone.
Similarly, CCRF-CEM cells treated with DEX and PPT as well as PGD2 also showed no
reduction in the levels of apoptosis compared to DEX treatment alone or DEX and PPT.
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Figure 3.7: The Effect of CRTh2 Activation by PGD2 on Apoptosis in CCRF-CEM
Cells
CCRF-CEM cells were treated with PGD2, DEX (0.1 µM), either 1.0 µM PPT (A; n=4) or
10 µM PPT (B; n=8) and various combinations of the three conditions for 48 hours to
determine apoptosis and cell death using flow cytometry. Additionally, these experiments
were completed with the higher concentration DEX (0.5 µM) and 1.0 µM PPT (C; n=4) or
10 µM PPT (D; n=6). Percentage of Annexin V positive 7-AAD negative cells were
assessed for single treatments and co-treatments. All data were represented as mean ±
SEM. Statistical differences were determined by using one-way repeated measures
ANOVA. Asterisks (* and ***) represent significance (P<0.05 and P<0.001, respectively)
vs control, and ns represents condition not significantly different vs control.
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My colleagues previously found that pre-treating primary Th2 cells with DEX and PPT
for 24 hours and then activating with PGD2 increased type 2 cytokine production [1].
Therefore, I also tested a similar setup. Cells were pre-treated with DEX and PPT for 24
hours to upregulate CRTh2 and then PGD2 was added with DEX for 48 hours and apoptosis
measured with Annexin V+/7-AAD- staining. Pre-treatment was performed using 0.01 µM
DEX and 10 µM PPT, as shown in Figure 3.6, the treatment seen to induce the largest
upregulation of CRTh2 surface levels. Stronger apoptosis inducing concentrations of DEX
(0.1-0.5 µM) as in (Fig. 3.2 and 3.7) and various PGD2 (0.1 – 1µM) concentrations were
chosen based on previous studies [1, 8]. The proportion of the cell population that was
Annexin V+/7-AAD-, i.e. early apoptosis, increased from 2% in non-treated cells to 20%
in those pre-treated but not activated (treated with 0.1-0.5 µM DEX) (Fig. 3.8). However,
the addition of PGD2 to activate the upregulated CRTh2 did not change the amount of
apoptosis induced by DEX alone.
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Figure 3.8: The Effect of DEX and PPT Pre-Treatment and CRTh2 Activation by
PGD2 on CCRF-CEM Cells
CCRF-CEM cells were pre-treated with 0.01 µM DEX and 10 µM PPT for 24 hours
followed by treatment with a higher concentration of DEX (0.1-0.5 µM; n=2) and PGD2
(0.1 µM, n=1; 1.0 µM; n=2). Apoptosis was assessed by flow cytometry staining and
analysis of proportion of Annexin V+ and 7-AAD- cells. Data represented as mean ±
standard deviation.
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3.5 GC and ERa Agonist Regulate CRTh2 at the Level of
Transcription
CRTh2 expression was initially shown to be a characteristic of Th2 but not Th1 cells [89]
and later demonstrated to be regulated by GATA3 during Th2 cell differentiation [321,
322]. More recently, CRTh2 expression within ILC2 was also associated with GATA3
expression [323]. Despite the importance of the CRTh2 pathway to type 2 inflammation,
relatively little is known regarding the molecular regulation of this gene.
The Cameron laboratory has shown that the CRTh2 promoter is transcriptionally activated
by GATA3 [96] and this activity is modified by TCR activation and NFAT inhibition of
GATA3 binding [318]. CRTh2 has also been shown to be regulated by genetic variation.
Indeed, a number of SNPs have been shown to associate with increased risk of asthma and
asthma severity [100] as well as other allergic phenotypes [102]. My colleagues have
shown that a SNP within the CRTh2 promoter 6388 bp upstream of the ATG (-6388G>A),
is associated with the development of asthma and that the A allele increased CRTh2
expression and response to PGD2 [103]. In silico analyses show that the CRTh2 (PTGDR2)
promoter contains conserved regions containing a number of putative transcription factor
binding sites as well as GREs, i.e. binding sites for GR, including one in the vicinity of
CRTh2-6388G>A (Fig. 3.9). Therefore, this aim examined whether the GC and estrogen
increase in CRTh2 expression occurs at the level of transcriptional activation and if the
CRTh2 promoter SNP -6388G>A alters this activity.
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Figure 3.9: CRTh2 Promoter Constructs
Mapping of the CRTh2 promoter. Putative GRE sites identified using MatInspector
analysis within the upstream region of CRTh2. CRTh2pro/Luc constructs generated of
short (1836 bp) and long (4336 bp) length containing 1 and 3 putative GREs, respectively
(A). Additional putative transcription factor binding sites and rs533116G>A location
labeled on CRTh2 promoter (B). Constructs representing the G (wild type) and A allele of
the CRTh2 promoter (CRTh2pro-6388G/Luc and CRTh2pro-6388A/Luc) were generated
and schematics identify variation between predicted transcription factor binding sites.
Abbreviations are as followed: base pairs, bp; chemoattractant receptor-homologous
molecule expressed on T helper 2 cell, CRTh2; conserved region, CR; forkhead box
transcription factors, FOXO; glucocorticoid response element, GRE; luciferase, Luc;
nuclear factor of activated T-cells, NFAT; promoter, pro; transcription start site, TSS; wild
type, WT. Created with Biorender.com.
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Transcriptional regulation of CRTh2 was studied using CRTh2 promoter reporter
constructs previously generated by our laboratory. The CRTh2pro-4513/Luc contains the
1836 bps immediately upstream of the transcription start site (TSS), 4513 bps relative to
the ATG (rATG) and has 1 putative GRE. The CRTh2pro-7013/Luc contains the 4336 bps
upstream of the TSS, 7013 bp rATG and contains 3 putative GRE sites (Fig. 3.9A).
To test my hypothesis that GC and ERa agonist induce CRTh2 promoter activation,
constructs were transiently transfected into CCRF-CEM cells treated with DEX (0.1 µM)
in the presence and absence of PPT (1.0 µM) for 22 hours and luciferase activity measured.
Promoter activity of both constructs was found to be significantly increased when control
was compared to DEX alone (P<0.05), and even more significantly increased with DEX
and PPT co-treatment (P<0.05; Fig. 3.10). Specifically, promoter activity at baseline level
was approximately 750 RLU and treatment with DEX increased promoter activity to ~1500
RLU. Promoter activity of the shorter construct (CRTh2pro-4513/Luc) was increased to
~1750 RLU with DEX and PPT co-treatment (Fig. 3.10A), and the longer construct
(CRTh2pro-7013/Luc) to ~2000 RLU (Fig. 3.10B); however, no significant difference was
found between the different CRTh2 promoter constructs.
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Figure 3.10: CRTh2 Promoter Activity in Response to DEX and PPT Co-Treatment
in CCRF-CEM Cells
CCRF-CEM cells were transiently transfected with CRTh2 luciferase reporter constructs
(CRTh2pro/Luc) and treated with DEX and PPT for 24 hours. Transcriptional activity of
the CRTh2 promoter was measured by fold increase of relative luciferase activity, corrected
for total protein abundance (BCA assay) and normalized to Renilla. Data for the shorter
construct (CRTh2pro-4513/Luc; A; n=5) and longer construct (CRTh2pro-7013/Luc; B;
n=10) were recorded as relative luciferase units (RLU) and represented as mean ± SEM.
Statistical differences were determined by using one-way repeated measures ANOVA.
Asterisk (*) represents significance (P<0.05) vs vehicle and number sign (#) represents
significance (P<0.05) between conditions.
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3.6 Genetic Variation Influences CRTh2 Transcriptional
Activation in Response to GC and ERa Agonist
The SNP, CRTh2-6388G>A, has been associated with increased CRTh2 expression and
allergic asthma [103]. Here, the promoter activity of the CRTh2pro-7013/Luc construct
with either allele, CRTh2pro-6388G/Luc and CRTh2pro-6388A/Luc (Fig. 3.9B), were
compared. Mapping of putative transcription factor binding sites identified an unperturbed
GRE site 6 bp from CRTh2-6388A; however, loss of a variety of other transcription factor
binding sites was predicted, including a site that binds NFAT, a transcription factor capable
of inhibiting CRTh2 expression [318]. This would indicate less competition for GR binding
in the A allele compared to the G allele.
To test if there are allele specific differences in the effect of GC and ERa signaling on
CRTh2 transcription, CCRF-CEM cells were transiently transfected with the CRTh2pro6388G/Luc or CRTh2pro-6388A/Luc construct and treated with DEX (0.1 µM) and/or PPT
(1.0 µM). CRTh2pro-6388G/Luc showed increased luciferase activity after DEX
treatment, from 1000 RLU of control to 1500 RLU (Fig. 3.11A). The addition of PPT (1.0
µM) co-treatment did not alter promoter activity from that induced by DEX alone (~1.5fold). Similar trends were found with analysis normalized to control; both DEX alone, and
in the presence of PPT resulted in ~2 fold induction of promoter activity (Fig. 3.11B). This
analysis minimized experimental variation. Similar to the G allele, cells transfected with
CRTh2pro-6388A/Luc promoter had a transcriptional activity of 1000 RLU in control cells,
and 1500 RLU with DEX treatment alone, though this was not a significant increase (Fig.
3.11A/C). Conversely, cells transfected with the CRTh2pro-6388A/Luc promoter did
exhibit a significant increase in transcriptional activity in cells treated with both DEX (0.1
µM) and PPT (1.0 µM), compared to DEX alone (2.5-fold, normalized to control (Fig.
3.11D).
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Figure 3.11: Transcriptional Responses to DEX and PPT in CRTh2-6388G and A
Alleles
CCRF-CEM cells were transiently transfected with CRTh2 promoter luciferase reporter
constructs (CRTh2pro-6388/Luc) of either CRTh2-6388G (A/B) or CRTh2-6388A (C/D)
allele. They were then treated with DEX in the presence and absence of PPT for 24 hours.
CRTh2 promoter activity was corrected for total protein abundance (BCA assay) and
normalized to Renilla. Data, recorded as relative luciferase units (RLU), was measured by
fold increase (A/C) and normalized to control (B/D). All data were represented as mean ±
SEM. Significance was determined by one-way repeated measures ANOVA; asterisks (*
and ***) represents statistical differences (P<0.05 and P<0.001, respectively) vs control
and number sign (#) represents differences between conditions. n=5.
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ERa Agonist Enhances GC Mediated Activity of CRTh2-6388A, but not
CRTh2-6388G
To further assess the influence of ERa agonist on GC induced activity of the CRTh2
genetic variants, DEX and PPT condition was normalized to DEX alone. Figure 3.12 shows
that while maximum activity of cells transfected with the CRTh2pro-6388G/Luc promoter
was seen with DEX (0.1 µM) and no added activity was shown with PPT (1.0 µM) cotreatment, maximum activity of the CRTh2pro-6388A/Luc promoter required both DEX
and PPT (Fig. 3.12A).
Experiments examining surface expression of CRTh2 on CCRF-CEM cells identified that
0.01 µM DEX and 10 µM PPT were the optimal concentrations to induce the largest
increased in CRTh2 (Fig. 3.6C/D). Preliminary experiments show that CCRF-CEM cells
treated with these concentrations of DEX and PPT compared to DEX alone exhibited
greater increases in promoter activity for the CRTh2pro-6388A/Luc (~2-fold) compared to
G (~1-fold) (Fig. 3.12B).
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Figure 3.12: CRTh2-6388G>A Comparison of Increase in CRTh2 Promoter Activity
with PPT Addition from DEX
CCRF-CEM cells were transiently transfected with CRTh2 luciferase reporter constructs
(CRTh2pro-6388/Luc) of G or A allele and then treated with DEX and/or PPT for 24 hours.
Promoter activity was corrected for total protein abundance (BCA assay) and normalized
to Renilla. Data, recorded as relative luciferase units (RLU), was measured by fold increase
and promoter activity induced by DEX+PPT was normalized to DEX. Co-treatment of 0.1
µM DEX and 1.0 µM PPT (A; n=5) was represented as mean ± SEM, and co-treatment
with 0.01 µM DEX and 10 µM PPT (B; n=2) was represented as mean ± standard deviation.
The statistical difference (A) were determined by a t-test.
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Chapter 4

4

Discussion

Women are more likely to have severe asthma than men [6]. A growing body of evidence
suggests this sex difference is associated with Th2 cell response to GC, both its effect on
apoptosis as well as gene regulation. Differential expression of CRTh2 may play a central
role, since activation of this receptor supports Th2 cell survival and type 2 cytokine
expression. This thesis investigated whether Th2 cell response to GC was altered by the
presence of estrogen and if this combined exposure increased CRTh2 expression.
Collectively, the data suggest that GR and ER crosstalk in Th2 cells affects their function
and may differ based on CRTh2 genotype.

4.1 Estrogen Receptor Signaling Reduce GC-Induced Apoptosis
Previously, an ERa selective agonist was reported to reduce DEX induced cell death,
though whether the effect was due to apoptosis was unclear [1]. My thesis continued this
line of investigation and showed that ERa agonist reduces GC mediated cell death by
attenuating apoptosis (Fig. 3.2). Multiple methods were used to assess ERa agonist effects.
Examining Annexin V+ alone showed approximately 10% more positive cells than with
Annexin V+/7-AAD- and FLICA staining, indicating the latter analyses were more
sensitive and specific measurements of early apoptosis. Both stains were performed within
the same experiment, as a head-to-head comparison. Despite the similarities between the
percentage of Annexin V+/7-AAD- and FLICA following GC treatment, differences were
observed. A larger reduction was seen with the ERa agonist (PPT) and 0.1 µM DEX with
the FLICA experiments, however, no reduction was found with co-treatment of all other
concentrations of DEX. This may be due to FLICA being an activated caspase assay with
a short window of opportunity for detection, suggesting that apoptosis induced by higher
concentrations of GC needed to be measured earlier than lower concentrations to ensure
the cell had not yet died. Moreover, a poly caspase FLICA was used, the reagent binding
covalently to caspase-1, -3, -4, -5, -6, -7, -8, and -9 [324]. It is important to note that
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caspase-1, -4, and -5 are responsible for pyroptosis [325]; therefore, we are only able to
confirm the induction and reduction of programmed cell death, and not differentiate
between apoptosis and pyroptosis. Future studies should consider the use of apoptotic
specific caspase-3, -6, -7, -8, and/or -9 FLICAs [325]. These results suggests that Th2 cells
exposed to both GC and ER agonist, as would occur within a female, may be less steroid
responsive to the apoptotic effects of GC than Th2 cells exposed to GC alone, similarly to
what would occur in males.
These results build upon previous studies regarding the pro-inflammatory effects of ERa,
as they suggest that ERa is in fact reducing the anti-inflammatory effect of GC. ERa
antagonists are used to treat breast cancer, as ERa signaling has been found to stimulate
proliferation [270, 326]. Moreover, in estrogen free environments, treatment with a
neurotoxin reduces the ratio of pro-apoptotic (BAD) and anti-apoptotic (Bcl-2) proteins,
thereby inducing apoptosis [327]. However, ERa but not ERb signaling was found to
maintain the ratio to levels as if no neurotoxin was present, implying a protection against
apoptosis effect [327]. This is an example of the Bcl-2 rheostat in action, the balance of
pro- and anti-apoptotic proteins [328, 329]. There may be a similar disequilibrium caused
by GC and ERa; GCs increase pro-apoptotic proteins [330], whereas ERa signaling
increase anti-apoptotic proteins [331]. The results observed herein suggest the antiapoptotic effects of ERa signaling are dampening the impact of GC.
The use of a selective agonist (PPT) allowed examination specifically of the effect of ERa,
however, the relevance of the data is limited by the chemical nature of the compound. A
more physiologically relevant approach would be to examine the effect of the sex hormone,
b-estradiol (E2), which signals through both ERa and ERb and exhibits differential effects
on cell growth and apoptosis, depending on the receptor isoform [332]. E2-ERa activate
PI3K/Akt and ERK/MAPK, responsible for preventing the apoptotic cascade and
progressing the cell cycle, while E2-ERb phosphorylates pathways involved in activating
caspase-3 and inducing apoptosis [332]. Additionally, E2 has been found to increase the
anti-apoptotic protein Bcl-2 [331]. Therefore, the effect of E2 was also examined and
revealed that CRTh2 surface expression on primary Th2 cells was increased by co-
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treatment with DEX and E2 treatment (Fig. 3.3) similar to DEX and PPT [1]. These
findings are similar to previous work showing increased CRTh2 expression on primary
Th2 cells following treatment with GC and the ERa agonist by flow cytometry as well as
mRNA and total protein abundance [1].
Examining E2 and GC on CRTh2 levels also acted as a dose-finding experiment to assess
the concentrations of E2 needed to impact GC-induced apoptosis. Analysis confirmed that
E2 co-treatment with GC significantly reduced apoptosis compared to GC alone (Fig. 3.4),
similar to findings with the selective ERa agonist PPT (Fig. 3.2). E2 treatment alone did
not alter level of apoptosis, though co-treating with GC and E2 resulted in significantly
fewer apoptotic cells than GC alone. Again, these results suggest Th2 cells in an estrogenrich environment are less responsive to the apoptotic effects of GC than those in an
estrogen-free/low environment. Contrary to the findings with ERa agonist, co-treatment
with GC and E2 resulted in apoptosis levels no different than control, suggesting the effect
of E2 was stronger than the selective ERa agonist.
These data highlight and build upon existing evidence of the pro-inflammatory and antiapoptotic nature of estrogen. In fact, Huber et al. found that E2 treatment of Th2 cells
increased Bcl-2, an anti-apoptotic factor, and suggested this may be the cause of the
enhanced survival of Th2 cells in females and not males during viral myocarditis [269].
Although the apoptotic trigger differed, these findings show the anti-apoptotic effects of
E2. It is important to note, however, that these studies identified a protective effect with
estrogen alone, in contrast to my study which suggests the effect was due to interfering
with GC (Fig. 3.4). Not only has the female sex hormone been shown to have an antiapoptotic effect, but E2 has also been shown to promote proliferation of epithelial cells in
mammary glands through modification of cell cycle genes [333]. In fact, estrogen has long
been shown to play a strong role in the development and growth of breast cancer [334,
335], and is the basis for the use of the anti-estrogen tamoxifen as a treatment for breast
cancer [336]. Additionally, global gene expression profiling identified that in ER positive
breast cancer cells, in response to E2, growth factor genes were up-regulated and proapoptotic genes were down-regulated [271]. Combined, these studies illustrate the
proliferative effects of estrogen, an area of research that needs to be further investigated in
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relation to GC. Collectively, this builds upon the knowledge that estrogen acts to inhibit
apoptosis of cells as well as promote growth. Further research needs to be conducted to
determine the specific effects of GC and E2 on pro- and anti-apoptotic genes in order to
understand the effects that the co-treatment has on the apoptotic cascade.
A limitation of this study is that the data showing that estrogen reduces GC-induced
apoptosis of primary Th2 cells could only be performed on a single cell line. Multiple
attempts were made to substantiate these findings in primary Th2 cells, using protocols
developed and previously employed by the Cameron laboratory [317, 318]. T cells were
isolated from peripheral blood and cultured in Th2 polarizing conditions (n=9). Contrary
to positive differentiations of preceding studies [317, 318], none of the cell lines exhibited
robust growth (Fig. 3.1). Unanticipated obstacles were faced and possibly the cause of the
cell death. These include incubator contamination and CO2 set-point errors resulting in
reduced CO2. Mammalian cell culture requires CO2 to provide nutrients for cell growth
and pH homeostasis [337]; therefore the cells may have been at a nutritional deficit. As
such, further experiments with Th2 cells differentiated from a number of donors would
help to validate the findings that estrogen reduces GC-induced apoptosis. It would be
particularly interesting to perform head-to-head comparisons of Th2 cells derived from
male and female donors, which would reveal differences related to the sex of the cells.

4.2 The Effects of Estrogen Signaling on CRTh2 in CCRF-CEM
Cells
Previously, Xue et al. found that activation of CRTh2 by PGD2 inhibits apoptosis induced
by IL-2 deprivation [8]. This thesis examined if CRTh2 activation could inhibit GCinduced apoptosis and whether the upregulation of CRTh2 (induced by GC and
ERa agonist) could enhance this effect. Due to difficulties with differentiating primary Th2
cell lines (Fig. 3.1), these experiments were performed on the immortalized lymphoblast T
cell line, CCRF-CEM, with the expectation of being repeated in the future on primary Th2
cells. Unlike primary cells, however, CRTh2 surface levels were not increased by cotreatment with DEX and E2 (Fig. 3.5).
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CRTh2 surface levels were previously seen to be increased on primary Th2 cells by GC
and the selective ERa agonist (PPT) [1]. Since E2 can act on both ERa and ERb, we also
examined the influence of PPT and found that co-treatment of CCRF-CEM cells with GC
and this ERa agonist significantly increased CRTh2 surface levels (Fig. 3.6). While lower
concentrations clearly showed an additive effect of these two agents (Fig. 3.6C/D), higher
concentrations of either GC alone (0.1 µM DEX) or ERa agonist alone (10 µM PPT) had
increased CRTh2 levels compared to baseline (Fig. 3.6B). This could suggest that each
agent plays a role in inducing CRTh2. Interestingly, the finding that the higher
concentration of ERa agonist increased CRTh2 expression builds upon existing evidence
that estrogen drives and inhibits both Th2 and Th1 cytokines and mediated diseases,
respectively [338], as CRTh2 is a marker for Th2 cells [95].
These experiments revealed the surprising result that in CCRF-CEM cells, E2 and ERa
agonist had different effects. This may be related to differential expression of ERa and
ERb in primary Th2 and CCRF-CEM cells. E2 binds to ERa and ERb homo- or
heterodimers [283]. Both receptors are encoded by different genes and have different
properties [280, 281]; therefore not only will expression vary, but the functional responses
do as well. Indeed, ERa and ERb appear to have different effects on inflammatory
responses in the context of asthma; ERa signaling was shown to be pro-inflammatory,
compared to the anti-inflammatory effects of ERb signaling. Experiments using selective
agonists and antagonists for the specific receptors have validated that ERa is involved in
increasing type 2 cytokines as well as eosinophils [261, 293] and ERb relaxes airway
smooth muscle as well as induces apoptosis though increasing pro-apoptotic factors [270,
294]. Specifically, one study found that treatment with E2 increased inflammatory effects
of CD4+ cells from male mice, and testing indicated these cells expressed ERa, thereby
demonstrating that when the sex hormone E2 binds to ERa, pro-inflammatory responses
are the result [261]. Based on these studies and my results showing that ERa activation
increases CRTh2, a receptor with inflammatory capabilities [8, 68, 109], treatment with a
selective ERb agonist may in fact reduce CRTh2 expression. The data from primary Th2
cells suggests they may have a higher ratio of ERa to ERb than CCRF-CEM cells. This
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could have resulted in E2 binding more to ERb dimers than ERa in CCRF-CEM cells,
leading to the differing outcome in the two cell lines. This is an area for future research: to
assess the effects of ERb agonist treatment alone, and in combination with GC. Ideally,
measurement of ESR1 and ESR2 levels in both primary Th2 cells and CCRF-CEM cells
and comparison of the ratio between the two cell types.
Baseline CRTh2 surface levels for CCRF-CEM were higher than those seen in primary
Th2 cells; non-treated CCRF-CEM cells were approximately 70% CRTh2 positive (Fig.
3.5), compared to the 40% positivity of primary Th2 cells (Fig. 3.3). Differences between
immortalized and primary cells have been shown elsewhere. The immortalized Sertoli cell
line (MSC-1) is morphologically and genetically similar to primary Sertoli cells, however,
inconsistent results were found between MSC-1 cell line and primary Sertoli cells [339,
340]. Therefore, while the goal was to use CCRF-CEM cells as a model Th2 cell line, these
experiments reveal they have limitations that may include differences in expression of
ERa, ERb or GPER.

4.3 PGD2 does not Reduce GC-Induced Apoptosis
Building on the existing evidence that CRTh2 activation is anti-apoptotic [8], this thesis
proposed that the increased expression of CRTh2 following GC and/or ERa agonist may
be protective against GC-induced apoptosis. The experiments performed in CCRF-CEM
cells, however, did not validate this hypothesis. Firstly, in this cell line the ERa agonist
did affect the level of apoptosis induced by GC treatment (Fig. 3.7). Secondly, when PGD2
was added to GC-alone or GC and ERa agonist co-treatment there was no reduction in
apoptosis (Fig. 3.7).
A possible explanation for ERa agonist reducing apoptosis in primary Th2 cells, but not
CCRF-CEM cells, may be that Th2 cells produce PGD2 [98] and may be capable of
autocrine/paracrine activation of CRTh2. Whether the immortalized CCRF-CEM cell line
produces PGD synthase and releases PGD2 is not known and should be examined in the
future. To assess whether the different outcomes between the two cell lines were related to
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this, PGD2 was added to the CCRF-CEM cells. Contrary to the suggestion made by Xue et
al. that CRTh2 activation by the ligand reduces apoptosis [8], this result was not observed
with GC and PGD2 co-treatment; no difference in apoptosis was seen in cells that received
GC and PGD2 compared to those treated with GC alone. Previous experiments revealed
that pre-treatment with GC and ERa agonist was required to see increased production of
type 2 cytokines following PGD2 stimulation [1]. Therefore, preliminary experiments were
performed pre-treating with GC and ERa agonist (to increase CRTh2) prior to PGD2
stimulation. However, still no difference in GC-induced apoptosis was observed (Fig. 3.8).
Combined, the findings illustrate that in CCRF-CEM cells activation of CRTh2 by PGD2
does not reduce GC-induced apoptosis.
Contrary to my hypothesis, cells treated with PGD2 and GC appeared to show no difference
in levels of apoptosis compared to GC alone (Fig. 3.7). Although this finding directly
contradicts the results of Xue et al., it is important to note that that study examined
apoptosis following IL-2 deprivation [8]. Specifically, it was suggested that activation of
the PI3K survival pathway was mediating the inhibition of apoptosis as CRTh2-PGD2
influxes calcium and stimulates the PI3K pathway, catalyzing BAD phosphorylation,
sequestering it in the cytosol and rendering it unable to inhibit Bcl-xl, leading to efflux of
cyt c and cleavage of caspase-3 to induce apoptosis [8]. However, through gene set
enrichment analyses, mutations have been identified upstream of the PI3K/Akt pathway in
CCRF-CEM cells, resulting in reduced ERK signaling [341]. These mutations in
combination with the differences observed between primary Th2 cells and CCRF-CEM
cells following DEX and PPT co-treatment indicate that these cell lines may not function
similarly.
Despite these conflicting results regarding the apoptotic influence of CRTh2-PGD2, if
CRTh2 activation increases GC-induced apoptosis this would build upon other evidence
reporting a pro-apoptotic effect. For instance, treatment of human osteoclasts differentiated
from PBMCs with PGD2 and a CRTh2 specific agonist induced apoptosis [342]. Moreover,
the mechanism behind this was through caspase-9 activation, identifying that CRTh2PGD2 activation in these cells intrinsically induces apoptosis [342]. Increased DNA
fragmentation and apoptotic bodies have also been observed following treatment of
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leukemia cells with PGD2 [343]. A study on lung adenocarcinoma-derived alveolar
epithelial cells has also identified that treatment with PGD2 induced apoptosis; however,
the researchers concede that they used antagonists for both DP1 and CRTh2 [344].
Collectively, these results suggest that the CRTh2-PGD2 pathway may have differential
effects on apoptosis depending on the cell type and cell death pathway.
In effect, the differences between the CCRF-CEM and primary Th2 cells in CRTh2
expression and apoptosis in response to GC and ERa agonist indicate the need for future
studies. Although the literature may appear conflicting in regard to the apoptotic nature of
CRTh2 activation by PGD2, further foundational experiments are needed to identify
whether the receptor is function in immortalized CCRF-CEM cells. Such experiments
could involve analysis of inflammatory cytokines in response to PGD2 activation, as we
have previously found this treatment to increase cytokines in primary Th2 cells [1].
Importantly, these studies need to be performed with primary Th2 cells.
The data show that Th2 cells treated with GC had more apoptosis than those exposed to
both GC and estrogen. These experiments were performed in vitro, however, and so the
strength of this conclusion is limited. Ideally, further studies examining Th2 cells exposed
to GC in vivo as well as comparing GC sensitivity of Th2 cells obtained from women and
men would help prove this mechanism.

4.4 Increase in CRTh2 Promoter Activity by GC and ERa Agonist
Within the CRTh2 promoter numerous putative GREs were found and so whether GC
exposure influences transcriptional activation of CRTh2 was examined. Cooperative crosstalk between ER and GR has been shown [345] and so it was hypothesized that ERa agonist
would enhance GC-induced activation of the CRTh2 promoter. In line with this, the results
confirmed that in response to GC (0.1 µM DEX), promoter activity was increased from
baseline and cells treated with GC and ERa agonist (1 µM PPT) exhibited significantly
higher promoter activity (Fig. 3.10). This was true for the shorter construct (CRTh2pro4513/Luc), containing one GRE, as well as the longer construct (CRTh2pro-7013/Luc),
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with three GREs. At baseline, both constructs exhibited activity ~1000 RLU (~3.5 fold
higher than empty vector), corresponding with the finding that CCRF-CEM cells expressed
CRTh2 on at the surface level with no treatment (Fig. 3.6). The fact that CRTh2 promoter
activity was increased with GC alone suggests that T cells exposed to GC undergo CRTh2
transcription and coincide with the finding that GC alone increased surface level of CRTh2
(Fig. 3.6A/B). A caveat, however, is that a condition with the ERa agonist alone was not
included here, since this effect was unexpected [1]. Therefore, we cannot rule out that
exposure to ERa agonist alone may also increase CRTh2 promoter activity. Activation of
the CRTh2 promoter is but one step in the process of a cell expressing CRTh2, however,
they do coincide with the increase in endogenous CRTh2 mRNA and total protein
abundance found with primary Th2 cells [1].
Transcriptional activation of CRTh2 by GC is in line with many other studies showing that
GC-GR complexes directly bind to GREs and increase transcription, a process called
transactivation [154, 156]. This has been shown for many anti-inflammatory genes
including p11 [157] and dual specificity phosphatase 1 [346]. Indeed, most studies showing
GC transactivation is for genes that act in an anti-inflammatory capacity, reducing
inflammation [347]. Whereas here, transactivation of the CRTh2 promoter would result in
a pro-inflammatory effect. This is not an original concept, rather increasing evidence has
been building on the pro-inflammatory effects of GC. Often, depending on the
concentration and chronicity of exposure, GC can elicit inflammatory effects in the central
nervous system [348]. Cortisol, the endogenous GC, has 10 times higher affinity for
mineralocorticoid receptors than GR; therefore basal levels of cortisol occupy most
mineralocorticoid receptors [349]. In a period of stress when cortisol is elevated, as
mineralocorticoid receptors are often already occupied, available cortisol binds to GR and
can elicit inflammatory responses [349]. For example, during acute stress there are
increased levels of cyclooxygenase-2 [350], NF-kB activity [351] and extracellular TNFa [352]. Additionally, in rats, basal levels of corticosterone that are higher than average
have been found to have increased pro-inflammatory mediators such as prostaglandin E2
[353]. Therefore the finding that GC increased CRTh2 promoter activity (Fig. 3.10) build
on the existing evidence that GR activation can have pro-inflammatory effects. This thesis
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used pharmacologically relevant concentrations of GC (0.01 - 1.0 µM). Indeed, oral
administration of dexamethasone (12 mg) results in plasma concentrations in the range of
0.2 µM [354]. However, some physiologic situations may result in even higher exposure.
For instance, blood cortisol concentrations in response to severe acute respiratory
syndrome (SARS)-induced stress have been recorded as high as 7.22 µM in human patients
[355], leading one to wonder about the repercussions of this medical scenario on CRTh2
transcription and the ensuing inflammation.
Both CRTh2pro-4513 and -7013/Luc had significant increases in transcriptional activity
with GC and ERa agonist co-treatment compared to baseline as well as treatment with GC
alone (Fig. 3.10). This supports the hypothesis that the surface level increase observed with
flow cytometry is due to a transcriptional effect. These experiments were performed in
vitro, however, and so the strength of this conclusion is limited. Further studies examining
Th2 cells from men and women exposed to GC in vivo would help to substantiate that these
conditions truly have a differential effect on CRTh2 expression.
These results build on other research showing cooperative cross-talk between ER and GR
and suggest that the enhanced effect on CRTh2 is due to ERa agonist and/or E2 increasing
GR binding to GRE. This was previously shown by GR-ChIP-seq: enrichment of GR at
GREs was observed with GC and E2 co-treatment [311]. The dynamic-assisted loading
model demonstrated that for some genes GR and ER do not compete for binding sites;
rather one receptor assists binding of the other [356]. Indeed, one study showed that
repression of pro-inflammatory genes was reduced the most by DEX and E2 co-treatment
(13/23 genes), compared to DEX alone (5/23 genes) and E2 alone (5/23 genes) [357].
Collectively, these studies support the conclusion that increased CRTh2 promoter activity
following DEX and PPT co-treatment is due to ERa enhancing the binding of GR, though
quantitative GR-ChIP experiments and a PPT alone condition are needed to confirm this
conclusion.
There was no additive effect when comparing the short (CRTh2pro-4513/Luc) and long
(CRTh2pro-7013/Luc) constructs (Fig. 3.10). This was surprising since previous research
has shown that genes with multiple GREs bound by GC have a significantly larger
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induction than genes with one GRE [358]. Interestingly, they also observed that some
genes, such as PER1, respond differently to lower vs higher concentrations of GC [358].
This may suggest that at lower GC concentrations (<0.1 µM), binding will only occur at
regions with the strongest GR-GRE interactions. Previous research has also found that
minute differences in sequence within and flanking the GRE, by even a single base pair,
have been shown to alter the binding of GR [358]. Therefore, a titration curve of DEX
should be explored, as 0.1 µM may have been an excess amount to observe differences, i.e.
a difference in the effect of GC on the longer vs shorter construct (3 vs 1 GRE) may be
observed using lower concentrations of DEX and/or CRTh2 promoter construct.

4.5 Genetic Variation within the CRTh2 Promoter Alters Response
to GC and ERa Agonist
Contrary to my hypothesis, this thesis showed CRTh2-6388A was not more
transcriptionally active than CRTh2-6388G at baseline or in response to GC alone or GC
and ERa agonist (Fig. 3.11). With CRTh2-6388G, GC activation significantly increased
promoter activity and this was not affected by the addition of ERa agonist. The CRTh26388A construct exhibited no significant increase in promoter activity with GC alone, but
did show a significant increase with GC and ERa agonist co-treatment. This suggests that
GC activates the G allele of the CRTh2 promoter, whereas the A allele needs both GC and
ERa agonist to significantly increase CRTh2 transcriptional activity.
Previously, in silico analysis (MatInspector) identified putative binding sites within the
CRTh2 promoter (Fig. 3.9). In the G allele, the presence of three GRE sites rationalizes the
increased promoter activity with GC, as GC-GR binds to GRE and transactivates the gene
[154]. At the location of the SNP, in addition to the GRE, the G allele has a number of sites
predicated to bind other transcription factors such as NFAT, FOXO and the enhancer
blocking insulator, CTCF [359]. While this may suggest there could be competition for GR
binding to this GRE, there is also the potential that one or more of these factors could
enhance GR binding, particularly the FOXO binding element. Indeed, in the promoter for
MuRF1, an atrophy regulatory gene, a GRE and FOXO binding element were found to be
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synergistically activated by GR and FOXO1 [183]. This was shown through a mutated
GRE and intact FOXO site strongly inhibiting the GC induced promoter induction;
however, when the GRE was intact and FOXO binding element was mutated, the induction
was completely abolished [183]. This study suggests that FOXO may stabilize GR binding
in the CRTh2 promoter, resulting in increased promoter activity following GC treatment as
seen in the CRTh2-6388G promoter. In contrast, analysis of transcription factor binding
sites predicted with the CRTh2-6388A allele showed that with the exception of the GRE,
at the location of the SNP, all of the previously listed putative binding sites were absent.
In light of the fact that exposure to GC alone did not significantly increase CRTh2-6388A
promoter activity, it is possible that the absence of FOXO failed to stabilize GR, as it may
do within the G allele [183], leading to reduced/insufficient GR binding and
transactivation.
The CRTh2-6388A allele had none of the other binding sites overlapping with the GRE.
As such, it is possible that the stabilizing effect of ERa agonist may have been needed to
increase GC-GR binding to the GRE, resulting in increased transcriptional activity seen
between GC alone and GC and ERa agonist treatment. Previous research found that
through differential CentriMo motif analysis, DEX and E2 treatment caused increased GR
enrichment at both GREs and EREs compared to DEX treatment alone [311]. My results
build upon this suggestion, however, further analyses are necessary to confirm this
mechanism. For example, quantitative ChIP analysis could be performed to examine
whether there is increased GR binding in the presence of ERa agonist. Since the ultimate
question is whether there is increased GR binding at the CRTh2-6388A vs G allele, Th2
cells from donors of AA and GG genotype would need to be compared using ChIP
sequencing, a technique with the potential to reveal site specific binding.
Examining the difference in promoter activity following GC and ERa agonist co-treatment
compared to GC alone showed a significantly larger induction for the CRTh2-6388A than
CRTh2-6388G allele (Fig. 3.12). Since the biggest increase in CRTh2 surface levels was
found with 0.01 µM DEX in combination with 10 µM PPT (Fig. 3.6C/D), additional
luciferase experiments were performed to investigate allelic differences with these
concentrations. This analysis suggests that GC and ERa agonist may result in CRTh2-
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6388A being more transcriptionally active than CRTh2-6388G (Fig. 3.12), though
statistical analysis could not be performed due to few experiments (n=2). Further
experiments are needed to confirm these results, but were not possible at this time.
A limitation of these transcriptional experiments is the absence of conditions examining
the effect of ERa agonist alone and/or E2 on CRTh2 transcriptional activity. Further, this
assay does not consider the gene in the context of chromatin structure, as it would be within
cells in vivo. Moreover, testing the effect of the sex hormones E2, as well as E1 and E3,
which are prominent at different phases of life would also be informative. Further research
should also include ChIP studies to identify the regions bound by GC-GR. A major
limitation of this aspect of the project is that ideally promoter experiments should be
followed up with assessing the response of Th2 cells from donors of GG and AA genotype.
This work was planned, but could not be completed due to difficulty with primary cell
culture and the inability to work in the laboratory due to pandemic precautions.
It is important to consider the physiological relevance of the GC and estrogen
concentrations used. The daily dosage of prescribed dexamethasone is 12-16 mg/day for 2
days [360, 361], maximally observed as 0.26 µM in circulating blood [354]. Therefore, the
concentration of 0.1 µM DEX used throughout all experiments in this thesis is a level that
may occur in vivo. ERa concentrations were initially chosen based published
concentrations that show the selectivity of PPT for ERa (Fig. 3.2) [362]. Concentrations
of E2 for treatments in primary Th2 cells experiments (Fig. 3.3-3.4) were chosen based on
papers studying GR-ER crosstalk (0.1 µM) [311]. However, we also wanted to consider
physiologically relevant concentrations. A review of the literature uncovered that plasma
levels of estrogen at the highest point during pregnancy can reach ~0.73 µM [363], those
in females on oral contraceptives were ~ 0.01 µM [364] and during the menstrual cycle
0.0015 µM [365]. Therefore, the lower concentration of 0.01 µM in CCRF-CEM cells (Fig
3.6) was more physiologically relevant. Experiments examining differences in E2
concentration were not informative, since CCRF-CEM showed no increase CRTh2 at any
concentration. Future experiments should include a positive control gene for E2 and focus
on concentrations E2 that represent physiologically and/or pharmacologically relevant
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concentrations. It is possible that these relatively high concentrations may exhibit
hysteresis, a phenomenon in which high concentrations inhibit the effect of a drug or
hormone and lower concentrations show effects [366]. As such, future experiments should
use concentrations similar to the lowest ones used in this dissertation.

4.6 Significance and Conclusions
It is well known that women are more likely to have a severe asthma diagnosis [6] and
severe symptoms requiring hospitalization [235]. This thesis shows that Th2 cells in an
environment similar to that of a female taking GC treatment (GC and estrogen) have more
CRTh2 compared to Th2 cells in a male-like environment (GC only). Additionally,
estrogen was found to reduce GC-induced apoptosis, supporting Th2 cell survival. Indeed,
this could suggest that when female asthmatics take GC, not only do CRTh2 levels increase
but their Th2 cells resist GC-induced apoptosis. This protective effect could allow for
proliferation of inflammatory Th2 cells, potentially explaining the positive association seen
in women between daily dose of inhaled corticosteroid, and circulating Th2 cells (App 1.2).
The ability of GC and estrogen to increase CRTh2 expression may prime Th2 cells to have
an even larger PGD2-mediated type 2 response, since these cytokines mediate many asthma
symptoms, such as bronchial construction and excess mucous production [80]. This all
suggests that GC may make asthmatic symptoms worse in some women, and supports the
transition to biologic therapy for asthma.
Interestingly, a selective CRTh2 antagonist, fevipriprant (QAW039), has been investigated
for therapeutic use [367]. In Phase II clinical trials, the daily administration of fevipriprant
to uncontrolled allergic asthmatics on low dose ICS for 12 weeks resulted in significant
improvement in pre-bronchodilator FEV1 compared to placebo [368]. Additionally,
moderate-to-severe asthmatics were also found to have reduced sputum eosinophilia and
improvements in post-bronchodilator FEV1 with the addition of fevipriprant to their
treatment regimen [369]. Despite promising results, the population of asthmatics that
would benefit most from this antagonist has yet to be discovered. Phase III trials have found
that fevipriprant has no effect on clinical outcome, specifically exacerbations per year, in
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moderate-to-severe asthmatics [370]. This may suggest that the benefits could be higher in
milder allergic asthmatics. There are however other targeted biologic medications that have
been approved for asthma including Dupilumab, an antagonist for IL4Ra [87], and
Mepolizumab, an antagonist for IL-5 [371].
Recently our laboratory found an association between the CRTh2-6388AA genotype,
severe asthma and increase in blood levels of CRTh2 mRNA in women, but not men (App.
4.1). The data generated here suggest this could be related to allele specific transcriptional
effects of GC and estrogen exposure. Indeed, the promoter experiments imply there may
be no difference in GC response across sexes if both have the G allele, while in those with
the A allele women may experience more GC-mediated CRTh2 transcription than men.
Overall, this study suggests CRTh2-6388G>A influences Th2 cell responses to GC in
women and that studies characterizing asthma and allergic inflammation may need to adopt
a sex specific analyses and approach to therapy.
In conclusion, this study shows that estrogen opposed the anti-inflammatory apoptotic
effect of GC, cooperated with GC to induce transcriptional activation of CRTh2 and that
this effect may differ based on CRTh2 genotype. Collectively, these results suggest that
women with severe asthma may have more Th2 cells due to estrogen reducing GC-induced
apoptosis and that the deleterious pro-inflammatory effects of GC may have a greater
impact on women than men.

78

References
1.

Vijeyakumaran, M., Effect of Estrogen and Glucocorticoid Signaling on Th2 cells
– Implications for Severe Asthma, in Pathology and Laboratory Medicine. 2018,
Western University: Electronic Thesis and Dissertation Repository.

2.

Jacobson, D.L., et al., Epidemiology and estimated population burden of selected
autoimmune diseases in the United States. Clin Immunol Immunopathol, 1997.
84(3): p. 223-43.

3.

Fairweather, D., S. Frisancho-Kiss, and N.R. Rose, Sex Differences in Autoimmune
Disease from a Pathological Perspective. Am J Pathol, 2008. 173(3): p. 600-9.

4.

Beeson, P.B., Age and sex associations of 40 autoimmune diseases. Am J Med,
1994. 96(5): p. 457-62.

5.

Ziegler, S.M. and M. Altfeld, Human Immunodeficiency Virus 1 and Type I
Interferons—Where Sex Makes a Difference. Front Immunol, 2017. 8.

6.

The ENFUMOSA cross-sectional European multicentre study of the clinical
phenotype of chronic severe asthma. European Network for Understanding
Mechanisms of Severe Asthma. Eur Respir J, 2003. 22(3): p. 470-7.

7.

Keselman, A. and N. Heller, Estrogen Signaling Modulates Allergic Inflammation
and Contributes to Sex Differences in Asthma. Front Immunol, 2015. 6.

8.

Xue, L., A. Barrow, and R. Pettipher, Novel function of CRTH2 in preventing
apoptosis of human Th2 cells through activation of the phosphatidylinositol 3kinase pathway. J Immunol, 2009. 182(12): p. 7580-6.

9.

Masoli M, F.D., Holt S, Beasley R and G.I.f.A. (GINA), The global burden of
asthma: executive summary of the GINA Dissemination Committee report. Allergy,
2004. 59(5): p. 469-478.

10.

Holgate, S.T., Genetic and environmental interaction in allergy and asthma. J
Allergy Clin Immunol, 1999. 104(6): p. 1139-46.

11.

Ober, C., Perspectives on the past decade of asthma genetics. J Allergy Clin
Immunol, 2005. 116(2): p. 274-8.

12.

Aierken, H., et al., Polymorphisms of the ADAM33 gene and chronic obstructive
pulmonary disease risk: a meta-analysis. Clin Respir J, 2014. 8(1): p. 108-15.

13.

Thomsen, S.F., Genetics of asthma: an introduction for the clinician, in Eur Clin
Respir J. 2015.

79

14.

Thomsen, S.F., et al., Estimates of asthma heritability in a large twin sample. Clin
Exp Allergy, 2010. 40(7): p. 1054-61.

15.

Bisgaard, H., et al., Gene-Environment Interaction in the Onset of Eczema in
Infancy: Filaggrin Loss-of-Function Mutations Enhanced by Neonatal Cat
Exposure, in PLoS Med. 2008.

16.

Levy, M.L., et al., International Primary Care Respiratory Group (IPCRG)
Guidelines: diagnosis of respiratory diseases in primary care. Prim Care Respir J,
2006. 15(1): p. 20-34.

17.

Brigham, E.P. and N.E. West, Diagnosis of asthma: diagnostic testing. Int Forum
Allergy Rhinol, 2015. 5 Suppl 1: p. S27-30.

18.

Busse, W.W. and R.F. Lemanske, Jr., Asthma. N Engl J Med, 2001. 344(5): p. 35062.

19.

Johansson SG1, H.J., Bousquet J, Bruijnzeel-Koomen C, Dreborg S, Haahtela T,
Kowalski ML, Mygind N, Ring J, van Cauwenberge P, van Hage-Hamsten M,
Wüthrich B and E.t.E.A.o.A.a.C.I.n.t. force., A revised nomenclature for allergy.
An EAACI position statement from the EAACI nomenclature task force. Allergy,
2001. 56(9): p. 813-24.

20.

Durham, S.R., et al., Blood eosinophils and eosinophil-derived proteins in allergic
asthma. J Allergy Clin Immunol, 1989. 84(6 Pt 1): p. 931-6.

21.

Walker, C., et al., Activated T cells and eosinophilia in bronchoalveolar lavages
from subjects with asthma correlated with disease severity. J Allergy Clin
Immunol, 1991. 88(6): p. 935-42.

22.

Robinson, D.S., et al., Predominant TH2-like bronchoalveolar T-lymphocyte
population in atopic asthma. N Engl J Med, 1992. 326(5): p. 298-304.

23.

Green, R.H., et al., Analysis of induced sputum in adults with asthma: identification
of subgroup with isolated sputum neutrophilia and poor response to inhaled
corticosteroids. Thorax, 2002. 57(10): p. 875-9.

24.

Zoratti, E., et al., Differentiating Asthma Phenotypes in Young Adults through
Polyclonal Cytokine Profiles. Ann Allergy Asthma Immunol, 2014. 113(1): p. 2530.

25.

Heijink, I.H., M.C. Nawijn, and T.L. Hackett, Airway epithelial barrier function
regulates the pathogenesis of allergic asthma. Clin Exp Allergy, 2014. 44(5): p.
620-30.

26.

Hammad, H. and B.N. Lambrecht, Dendritic cells and airway epithelial cells at the
interface between innate and adaptive immune responses. Allergy, 2011. 66(5): p.
579-87.

80

27.

Gallucci, S., M. Lolkema, and P. Matzinger, Natural adjuvants: endogenous
activators of dendritic cells. Nat Med, 1999. 5(11): p. 1249-55.

28.

Leung, T.F., et al., Increased macrophage-derived chemokine in exhaled breath
condensate and plasma from children with asthma. Clin Exp Allergy, 2004. 34(5):
p. 786-91.

29.

Gong, J.L., et al., Interstitial lung macrophages interact with dendritic cells to
present antigenic peptides derived from particulate antigens to T cells.
Immunology, 1994. 81(3): p. 343-51.

30.

Venet, A., et al., Enhanced alveolar macrophage-mediated antigen-induced Tlymphocyte proliferation in sarcoidosis. J Clin Invest, 1985. 75(1): p. 293-301.

31.

Watts, C., Capture and processing of exogenous antigens for presentation on MHC
molecules. Annu Rev Immunol, 1997. 15: p. 821-50.

32.

al, C.C.e., B70/B7-2 is identical to CD86 and is the major functional ligand for
CD28 expressed on human dendritic cells, in J Exp Med. 1994. p. 1841-7.

33.

Sallusto, F., et al., Distinct patterns and kinetics of chemokine production regulate
dendritic cell function. Eur J Immunol, 1999. 29(5): p. 1617-25.

34.

Randolph, G.J., G. Sanchez-Schmitz, and V. Angeli, Factors and signals that
govern the migration of dendritic cells via lymphatics: recent advances. Springer
Semin Immunopathol, 2005. 26(3): p. 273-87.

35.

Hammad, H. and B.N. Lambrecht, Barrier Epithelial Cells and the Control of Type
2 Immunity. Immunity, 2015. 43(1): p. 29-40.

36.

Rank, M.A., et al., IL-33-activated dendritic cells induce an atypical TH2-type
response. J Allergy Clin Immunol, 2009. 123(5): p. 1047-54.

37.

Hammad, H., et al., House dust mite allergen induces asthma via TLR4 triggering
of airway structural cells. Nat Med, 2009. 15(4): p. 410-6.

38.

Vermaelen, K.Y., et al., Specific migratory dendritic cells rapidly transport antigen
from the airways to the thoracic lymph nodes. J Exp Med, 2001. 193(1): p. 51-60.

39.

Lambrecht, B.N., R.A. Pauwels, and B. Fazekas De St Groth, Induction of rapid T
cell activation, division, and recirculation by intratracheal injection of dendritic
cells in a TCR transgenic model. J Immunol, 2000. 164(6): p. 2937-46.

40.

Lim, T.S., et al., CD80 and CD86 differentially regulate mechanical interactions
of T-cells with antigen-presenting dendritic cells and B-cells. PLoS One, 2012.
7(9): p. e45185.

81

41.

Tao, X., et al., Strength of TCR signal determines the costimulatory requirements
for Th1 and Th2 CD4+ T cell differentiation. J Immunol, 1997. 159(12): p. 595663.

42.

Chen, W., et al., Conversion of peripheral CD4+CD25- naive T cells to
CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor
Foxp3. J Exp Med, 2003. 198(12): p. 1875-86.

43.

Nurieva, R.I., et al., Generation of T follicular helper cells is mediated by
interleukin-21 but independent of T helper 1, 2, or 17 cell lineages. Immunity,
2008. 29(1): p. 138-49.

44.

Hsieh, C.S., et al., Development of TH1 CD4+ T cells through IL-12 produced by
Listeria-induced macrophages. Science, 1993. 260(5107): p. 547-9.

45.

Swain, S.L., et al., IL-4 directs the development of Th2-like helper effectors. J
Immunol, 1990. 145(11): p. 3796-806.

46.

Park, H., et al., A distinct lineage of CD4 T cells regulates tissue inflammation by
producing interleukin 17. Nat Immunol, 2005. 6(11): p. 1133-41.

47.

Boes, M., et al., T-cell engagement of dendritic cells rapidly rearranges MHC class
II transport. Nature, 2002. 418(6901): p. 983-8.

48.

Rogers, P.R. and M. Croft, Peptide dose, affinity, and time of differentiation can
contribute to the Th1/Th2 cytokine balance. J Immunol, 1999. 163(3): p. 1205-13.

49.

Mosmann, T.R. and R.L. Coffman, TH1 and TH2 cells: different patterns of
lymphokine secretion lead to different functional properties. Annu Rev Immunol,
1989. 7: p. 145-73.

50.

Killar, L., et al., Cloned, Ia-restricted T cells that do not produce interleukin 4(IL
4)/B cell stimulatory factor 1(BSF-1) fail to help antigen-specific B cells. J
Immunol, 1987. 138(6): p. 1674-9.

51.

Szabo, S.J., et al., A novel transcription factor, T-bet, directs Th1 lineage
commitment. Cell, 2000. 100(6): p. 655-69.

52.

Lazarevic, V., et al., T-bet represses T(H)17 differentiation by preventing Runx1mediated activation of the gene encoding RORgammat. Nat Immunol, 2011. 12(1):
p. 96-104.

53.

Lighvani, A.A., et al., T-bet is rapidly induced by interferon-gamma in lymphoid
and myeloid cells. Proc Natl Acad Sci U S A, 2001. 98(26): p. 15137-42.

54.

Kaplan, M.H., et al., Impaired IL-12 responses and enhanced development of Th2
cells in Stat4-deficient mice. Nature, 1996. 382(6587): p. 174-7.

82

55.

Kaplan, M.H., et al., Stat6 is required for mediating responses to IL-4 and for
development of Th2 cells. Immunity, 1996. 4(3): p. 313-9.

56.

Kurata, H., et al., Ectopic expression of activated Stat6 induces the expression of
Th2-specific cytokines and transcription factors in developing Th1 cells. Immunity,
1999. 11(6): p. 677-88.

57.

Zhu, J., et al., Conditional deletion of Gata3 shows its essential function in T(H)1T(H)2 responses. Nat Immunol, 2004. 5(11): p. 1157-65.

58.

Maggi, E., et al., Reciprocal regulatory effects of IFN-gamma and IL-4 on the in
vitro development of human Th1 and Th2 clones. J Immunol, 1992. 148(7): p. 21427.

59.

Suzuki, Y., et al., Interferon-gamma: the major mediator of resistance against
Toxoplasma gondii. Science, 1988. 240(4851): p. 516-8.

60.

Kopf, M., et al., Disruption of the murine IL-4 gene blocks Th2 cytokine responses.
Nature, 1993. 362(6417): p. 245-8.

61.

Avni, O., et al., T(H) cell differentiation is accompanied by dynamic changes in
histone acetylation of cytokine genes. Nat Immunol, 2002. 3(7): p. 643-51.

62.

Kubo, M., et al., CD28 costimulation accelerates IL-4 receptor sensitivity and IL4-mediated Th2 differentiation. J Immunol, 1999. 163(5): p. 2432-42.

63.

Yamane, H., J. Zhu, and W.E. Paul, Independent roles for IL-2 and GATA-3 in
stimulating naive CD4+ T cells to generate a Th2-inducing cytokine environment.
J Exp Med, 2005. 202(6): p. 793-804.

64.

Zhu, J., et al., Stat5 activation plays a critical role in Th2 differentiation. Immunity,
2003. 19(5): p. 739-48.

65.

Takemoto, N., et al., Cutting edge: chromatin remodeling at the IL-4/IL-13
intergenic regulatory region for Th2-specific cytokine gene cluster. J Immunol,
2000. 165(12): p. 6687-91.

66.

Yamashita, M., et al., Essential role of GATA3 for the maintenance of type 2 helper
T (Th2) cytokine production and chromatin remodeling at the Th2 cytokine gene
loci. J Biol Chem, 2004. 279(26): p. 26983-90.

67.

Messi, M., et al., Memory and flexibility of cytokine gene expression as separable
properties of human T(H)1 and T(H)2 lymphocytes. Nat Immunol, 2003. 4(1): p.
78-86.

68.

Xue, L., et al., Prostaglandin D2 causes preferential induction of proinflammatory
Th2 cytokine production through an action on chemoattractant receptor-like
molecule expressed on Th2 cells. J Immunol, 2005. 175(10): p. 6531-6.

83

69.

Beale, J., et al., Rhinovirus induced IL-25 in asthma exacerbation drives type-2
immunity and allergic pulmonary inflammation. Sci Transl Med, 2014. 6(256): p.
256ra134.

70.

Soumelis, V., et al., Human epithelial cells trigger dendritic cell mediated allergic
inflammation by producing TSLP. Nat Immunol, 2002. 3(7): p. 673-80.

71.

Kearley, J., et al., Cigarette smoke silences innate lymphoid cell function and
facilitates an exacerbated type I interleukin-33-dependent response to infection.
Immunity, 2015. 42(3): p. 566-79.

72.

Weng, C.M., et al., Aryl hydrocarbon receptor activation by diesel exhaust
particles mediates epithelium-derived cytokines expression in severe allergic
asthma. Allergy, 2018. 73(11): p. 2192-2204.

73.

Salimi, M., et al., A role for IL-25 and IL-33–driven type-2 innate lymphoid cells
in atopic dermatitis, in J Exp Med. 2013. p. 2939-50.

74.

Besnard, A.G., et al., IL-33-activated dendritic cells are critical for allergic airway
inflammation. Eur J Immunol, 2011. 41(6): p. 1675-86.

75.

Halim, T., et al., Group 2 Innate Lymphoid Cells Are Critical for the Initiation of
Adaptive T Helper 2 Cell-Mediated Allergic Lung Inflammation, in Immunity.
2014. p. 425-35.

76.

Coffman, R.L., et al., Antibody to interleukin-5 inhibits helminth-induced
eosinophilia in mice. Science, 1989. 245(4915): p. 308-10.

77.

Palframan, R.T., et al., Mechanisms of Acute Eosinophil Mobilization from the
Bone Marrow Stimulated by Interleukin 5: The Role of Specific Adhesion Molecules
and Phosphatidylinositol 3-Kinase. J Exp Med, 1998. 188(9): p. 1621-32.

78.

Shi, H.Z., et al., Effect of inhaled interleukin-5 on airway hyperreactivity and
eosinophilia in asthmatics. Am J Respir Crit Care Med, 1998. 157(1): p. 204-9.

79.

Tliba, O., et al., IL-13 enhances agonist-evoked calcium signals and contractile
responses in airway smooth muscle, in Br J Pharmacol. 2003. p. 1159-62.

80.

Zhu, Z., et al., Pulmonary expression of interleukin-13 causes inflammation, mucus
hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin
production, in J Clin Invest. 1999. p. 779-88.

81.

de Vries, J.E., The role of IL-13 and its receptor in allergy and inflammatory
responses. J Allergy Clin Immunol, 1998. 102(2): p. 165-9.

82.

Coffman, R.L., et al., B cell stimulatory factor-1 enhances the IgE response of
lipopolysaccharide-activated B cells. J Immunol, 1986. 136(12): p. 4538-41.

84

83.

Pawankar, R., et al., Nasal mast cells in perennial allergic rhinitics exhibit
increased expression of the Fc epsilonRI, CD40L, IL-4, and IL-13, and can induce
IgE synthesis in B cells. J Clin Invest, 1997. 99(7): p. 1492-9.

84.

Bischoff, S.C., et al., IL-4 enhances proliferation and mediator release in mature
human mast cells, in Proc Natl Acad Sci U S A. 1999. p. 8080-5.

85.

Lewis, R.A., et al., Prostaglandin D2 generation after activation of rat and human
mast cells with anti-IgE. J Immunol, 1982. 129(4): p. 1627-31.

86.

Busse, W.W., et al., Safety profile, pharmacokinetics, and biologic activity of
MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with
mild asthma. J Allergy Clin Immunol, 2010. 125(6): p. 1237-1244.e2.

87.

Wenzel, S., et al., Dupilumab in persistent asthma with elevated eosinophil levels.
N Engl J Med, 2013. 368(26): p. 2455-66.

88.

Piper, E., et al., A phase II placebo-controlled study of tralokinumab in moderateto-severe asthma. Eur Respir J, 2013. 41(2): p. 330-8.

89.

Nagata, K., et al., Selective expression of a novel surface molecule by human Th2
cells in vivo. J Immunol, 1999. 162(3): p. 1278-86.

90.

Marchese, A., et al., Discovery of three novel orphan G-protein-coupled receptors.
Genomics, 1999. 56(1): p. 12-21.

91.

Nagata, K., et al., CRTH2, an orphan receptor of T-helper-2-cells, is expressed on
basophils and eosinophils and responds to mast cell-derived factor(s). FEBS Lett,
1999. 459(2): p. 195-9.

92.

Mjosberg, J.M., et al., Human IL-25- and IL-33-responsive type 2 innate lymphoid
cells are defined by expression of CRTH2 and CD161. Nat Immunol, 2011. 12(11):
p. 1055-62.

93.

Moon, T.C., et al., Expression of DP2 (CRTh2), a Prostaglandin D2 Receptor, in
Human Mast Cells, in PLoS One. 2014.

94.

Shirasaki, H., et al., Accumulation of CRTH2-positive leukocytes in human allergic
nasal mucosa. Ann Allergy Asthma Immunol, 2009. 102(2): p. 110-5.

95.

Cosmi, L., et al., CRTH2 is the most reliable marker for the detection of circulating
human type 2 Th and type 2 T cytotoxic cells in health and disease. Eur J Immunol,
2000. 30(10): p. 2972-9.

96.

Quapp, R., N. Madsen, and L. Cameron, Characterization of the promoter of human
CRTh2, a prostaglandin D2 receptor. Biochem Biophys Res Commun, 2007.
363(4): p. 948-53.

85

97.

Satoh, T., et al., Prostaglandin D2 plays an essential role in chronic allergic
inflammation of the skin via CRTH2 receptor. J Immunol, 2006. 177(4): p. 2621-9.

98.

Fajt, M.L., et al., Prostaglandin D(2) pathway upregulation: relation to asthma
severity, control, and TH2 inflammation. J Allergy Clin Immunol, 2013. 131(6): p.
1504-12.

99.

Palikhe, N.S., et al., Elevated levels of circulating CD4(+) CRTh2(+) T cells
characterize severe asthma. Clin Exp Allergy, 2016. 46(6): p. 825-36.

100.

Huang, J.L., et al., Sequence variants of the gene encoding chemoattractant
receptor expressed on Th2 cells (CRTH2) are associated with asthma and
differentially influence mRNA stability. Hum Mol Genet, 2004. 13(21): p. 2691-7.

101.

Wang, J., et al., Genetic variations in chemoattractant receptor expressed on Th2
cells (CRTH2) is associated with asthma susceptibility in Chinese children. Mol
Biol Rep, 2009. 36(6): p. 1549-53.

102.

Cameron, L., et al., Genetic variation in CRTh2 influences development of allergic
phenotypes. Allergy, 2009. 64(10): p. 1478-85.

103.

Campos Alberto, E., et al., The single nucleotide polymorphism CRTh2 rs533116
is associated with allergic asthma and increased expression of CRTh2. Allergy,
2012. 67(11): p. 1357-64.

104.

Hirai, H., et al., Prostaglandin D2 selectively induces chemotaxis in T helper type
2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J
Exp Med, 2001. 193(2): p. 255-61.

105.

Monneret, G., et al., Prostaglandin D2 is a potent chemoattractant for human
eosinophils that acts via a novel DP receptor. Blood, 2001. 98(6): p. 1942-8.

106.

Caughey, G.E., et al., Roles of cyclooxygenase (COX)-1 and COX-2 in prostanoid
production by human endothelial cells: selective up-regulation of prostacyclin
synthesis by COX-2. J Immunol, 2001. 167(5): p. 2831-8.

107.

Hamberg, M. and B.B. Fredholm, Isomerization of prostaglandin H2 into
prostaglandin D2 in the presence of serum albumin. Biochim Biophys Acta, 1976.
431(1): p. 189-83.

108.

Nagata, K. and H. Hirai, The second PGD(2) receptor CRTH2: structure,
properties, and functions in leukocytes. Prostaglandins Leukot Essent Fatty Acids,
2003. 69(2-3): p. 169-77.

109.

Xue, L., et al., Inhibition of PI3K and calcineurin suppresses chemoattractant
receptor-homologous molecule expressed on Th2 cells (CRTH2)-dependent
responses of Th2 lymphocytes to prostaglandin D(2). Biochem Pharmacol, 2007.
73(6): p. 843-53.

86

110.

Spik, I., et al., Activation of the prostaglandin D2 receptor DP2/CRTH2 increases
allergic inflammation in mouse. J Immunol, 2005. 174(6): p. 3703-8.

111.

Gallant, M.A., et al., Differential regulation of the signaling and trafficking of the
two prostaglandin D2 receptors, prostanoid DP receptor and CRTH2. Eur J
Pharmacol, 2007. 557(2-3): p. 115-23.

112.

Gyles, S.L., et al., A dominant role for chemoattractant receptor-homologous
molecule expressed on T helper type 2 (Th2) cells (CRTH2) in mediating
chemotaxis of CRTH2+ CD4+ Th2 lymphocytes in response to mast cell
supernatants. Immunology, 2006. 119(3): p. 362-8.

113.

Tanaka, K., et al., Effects of prostaglandin D2 on helper T cell functions. Biochem
Biophys Res Commun, 2004. 316(4): p. 1009-14.

114.

Morgan, D.A., F.W. Ruscetti, and R. Gallo, Selective in vitro growth of T
lymphocytes from normal human bone marrows. Science, 1976. 193(4257): p.
1007-8.

115.

Cerezo, A., et al., IL-2 deprivation triggers apoptosis which is mediated by c-Jun
N-terminal kinase 1 activation and prevented by Bcl-2. Cell Death Differ, 1999.
6(1): p. 87-94.

116.

Miller, M.R., et al., Standardisation of spirometry. Eur Respir J, 2005. 26(2): p.
319-38.

117.

Pellegrino, R., et al., Interpretative strategies for lung function tests. Eur Respir J,
2005. 26(5): p. 948-68.

118.

Dekker, F.W., et al., Validity of peak expiratory flow measurement in assessing
reversibility of airflow obstruction. Thorax, 1992. 47(3): p. 162-6.

119.

Crapo RO, C.R., Coates AL, Enright PL, Hankinson JL, Irvin CG, MacIntyre NR,
McKay RT, Wanger JS, Anderson SD, Cockcroft DW, Fish JE, Sterk PJ.,
Guidelines for methacholine and exercise challenge testing-1999. Am J Respir Crit
Care Med., 2000. 161(1): p. 309-29.

120.

Pizzichini, E., et al., Measuring airway inflammation in asthma: eosinophils and
eosinophilic cationic protein in induced sputum compared with peripheral blood. J
Allergy Clin Immunol, 1997. 99(4): p. 539-44.

121.

Becker, A.B. and E.M. Abrams, Asthma guidelines: the Global Initiative for
Asthma in relation to national guidelines. Curr Opin Allergy Clin Immunol, 2017.
17(2): p. 99-103.

122.

Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of
Asthma-Summary Report 2007. J Allergy Clin Immunol, 2007. 120(5 Suppl): p.
S94-138.

87

123.

Chung, K.F., et al., International ERS/ATS guidelines on definition, evaluation and
treatment of severe asthma. Eur Respir J, 2014. 43(2): p. 343-73.

124.

Barnes, P.J. and A.J. Woolcock, Difficult asthma. Eur Respir J, 1998. 12(5): p.
1209-18.

125.

Li, D., et al., Prospective study of hospitalization for asthma. A preliminary risk
factor model. Am J Respir Crit Care Med, 1995. 151(3 Pt 1): p. 647-55.

126.

Thomsen, S.F., et al., A study of asthma severity in adult twins. Clin Respir J, 2012.
6(4): p. 228-37.

127.

Pauwels, R.A., et al., Effect of inhaled formoterol and budesonide on exacerbations
of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET)
International Study Group. N Engl J Med, 1997. 337(20): p. 1405-11.

128.

Juniper, E.F., et al., Effect of long-term treatment with an inhaled corticosteroid
(budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroiddependent asthmatics. Am Rev Respir Dis, 1990. 142(4): p. 832-6.

129.

Nelson, J.A., et al., Effect of long-term salmeterol treatment on exercise-induced
asthma. N Engl J Med, 1998. 339(3): p. 141-6.

130.

Barnes, P.J., Scientific rationale for inhaled combination therapy with long-acting
beta2-agonists and corticosteroids. Eur Respir J, 2002. 19(1): p. 182-91.

131.

Lemanske, R.F., Jr., et al., Inhaled corticosteroid reduction and elimination in
patients with persistent asthma receiving salmeterol: a randomized controlled trial.
JAMA, 2001. 285(20): p. 2594-603.

132.

Lazarus, S.C., et al., Long-acting beta2-agonist monotherapy vs continued therapy
with inhaled corticosteroids in patients with persistent asthma: a randomized
controlled trial. Jama, 2001. 285(20): p. 2583-93.

133.

GINA, GINA Difficult-To-Treat & Severe Asthma in adolescent and adult patients:
Diagnosis and Management. 2019.

134.

Coutinho, A.E. and K.E. Chapman, The anti-inflammatory and immunosuppressive
effects of glucocorticoids, recent developments and mechanistic insights, in Mol
Cell Endocrinol. 2011. p. 2-13.

135.

Mulrow, P.J. and B.H. Forman, The tissue effects of mineralocorticoids. Am J Med,
1972. 53(5): p. 561-72.

136.

Mason, H.L., W.M. Hoehn, and E.C. Kendall, CHEMICAL STUDIES OF THE
SUPRARENAL CORTEX: IV. STRUCTURES OF COMPOUNDS C, D, E, F, AND
G. Journal of Biological Chemistry, 1938. 124(2): p. 459-474.

88

137.

Carryer, H.M., et al., Effects of cortisone on bronchial asthma and hay fever
occurring in subjects sensitive to ragweed pollen. Proc Staff Meet Mayo Clin, 1950.
25(17): p. 482-6.

138.

CONTROLLED trial of effects of cortisone acetate in status asthmaticus; report to
the Medical Research Council by the subcommittee on clinical trials in asthma.
Lancet, 1956. 271(6947): p. 803-6.

139.

Wei, L., T.M. MacDonald, and B.R. Walker, Taking glucocorticoids by
prescription is associated with subsequent cardiovascular disease. Ann Intern
Med, 2004. 141(10): p. 764-70.

140.

van Staa, T.P., et al., Children and the risk of fractures caused by oral
corticosteroids. J Bone Miner Res, 2003. 18(5): p. 913-8.

141.

Gurwitz, J.H., et al., Glucocorticoids and the risk for initiation of hypoglycemic
therapy. Arch Intern Med, 1994. 154(1): p. 97-101.

142.

Brown, H.M., G. Storey, and W.H.S. George, Beclomethasone Dipropionate: A
New Steroid Aerosol for the Treatment of Allergic Asthma. Br Med J, 1972.
1(5800): p. 585-90.

143.

Hollenberg, S.M., et al., Primary structure and expression of a functional human
glucocorticoid receptor cDNA. Nature, 1985. 318(6047): p. 635-41.

144.

Evans, R.M., The steroid and thyroid hormone receptor superfamily. Science,
1988. 240(4854): p. 889-95.

145.

Luisi, B.F., et al., Crystallographic analysis of the interaction of the glucocorticoid
receptor with DNA. Nature, 1991. 352(6335): p. 497-505.

146.

Freedman, L.P., Anatomy of the steroid receptor zinc finger region. Endocr Rev,
1992. 13(2): p. 129-45.

147.

Schena, M., L.P. Freedman, and K.R. Yamamoto, Mutations in the glucocorticoid
receptor zinc finger region that distinguish interdigitated DNA binding and
transcriptional enhancement activities. Genes Dev, 1989. 3(10): p. 1590-601.

148.

de Waal, R.M., The anti-inflammatory activity of glucocorticoids. Mol Biol Rep,
1994. 19(2): p. 81-8.

149.

Hollenberg, S.M. and R.M. Evans, Multiple and cooperative trans-activation
domains of the human glucocorticoid receptor. Cell, 1988. 55(5): p. 899-906.

150.

Picard, D. and K.R. Yamamoto, Two signals mediate hormone-dependent nuclear
localization of the glucocorticoid receptor. EMBO J, 1987. 6(11): p. 3333-40.

89

151.

Johnson, J.L. and D.O. Toft, A novel chaperone complex for steroid receptors
involving heat shock proteins, immunophilins, and p23. 1994.

152.

Peattie, D.A., et al., Expression and characterization of human FKBP52, an
immunophilin that associates with the 90-kDa heat shock protein and is a
component of steroid receptor complexes. Proc Natl Acad Sci U S A, 1992. 89(22):
p. 10974-8.

153.

van der Velden, V.H., Glucocorticoids: mechanisms of action and antiinflammatory potential in asthma. Mediators Inflamm, 1998. 7(4): p. 229-37.

154.

Scheidereit, C., et al., The glucocorticoid receptor binds to defined nucleotide
sequences near the promoter of mouse mammary tumour virus. Nature, 1983.
304(5928): p. 749-52.

155.

Parker, M., Enhancer elements activated by steroid hormones? Nature, 1983.
304(5928): p. 687-8.

156.

Beato, M., M. Truss, and S. Chavez, Control of transcription by steroid hormones.
Ann N Y Acad Sci, 1996. 784: p. 93-123.

157.

Yao, X.L., et al., Dexamethasone alters arachidonate release from human
epithelial cells by induction of p11 protein synthesis and inhibition of
phospholipase A2 activity. J Biol Chem, 1999. 274(24): p. 17202-8.

158.

Beato, M., Gene regulation by steroid hormones. Cell, 1989. 56(3): p. 335-44.

159.

Zaret, K.S. and K.R. Yamamoto, Reversible and persistent changes in chromatin
structure accompany activation of a glucocorticoid-dependent enhancer element.
Cell, 1984. 38(1): p. 29-38.

160.

Schieven, G.L., The p38alpha kinase plays a central role in inflammation. Curr
Top Med Chem, 2009. 9(11): p. 1038-48.

161.

Slack, D.N., et al., Distinct binding determinants for ERK2/p38alpha and JNK map
kinases mediate catalytic activation and substrate selectivity of map kinase
phosphatase-1. J Biol Chem, 2001. 276(19): p. 16491-500.

162.

Tchen, C.R., et al., Glucocorticoid Regulation of Mouse and Human Dual
Specificity Phosphatase 1 (DUSP1) Genes: UNUSUAL CIS-ACTING ELEMENTS
AND UNEXPECTED EVOLUTIONARY DIVERGENCE*, in J Biol Chem. 2010. p.
2642-52.

163.

Clark, A.R., MAP kinase phosphatase 1: a novel mediator of biological effects of
glucocorticoids? J Endocrinol, 2003. 178(1): p. 5-12.

164.

Barnes, P.J., Molecular mechanisms of steroid action in asthma. J Allergy Clin
Immunol, 1996. 97(1 Pt 2): p. 159-68.

90

165.

Konig, H., et al., Interference between pathway-specific transcription factors:
glucocorticoids antagonize phorbol ester-induced AP-1 activity without altering
AP-1 site occupation in vivo. Embo j, 1992. 11(6): p. 2241-6.

166.

De Bosscher, K., et al., Glucocorticoid-mediated repression of nuclear factorkappaB-dependent transcription involves direct interference with transactivation.
Proc Natl Acad Sci U S A, 1997. 94(25): p. 13504-9.

167.

Stocklin, E., et al., Functional interactions between Stat5 and the glucocorticoid
receptor. Nature, 1996. 383(6602): p. 726-8.

168.

Liberman, A.C., et al., Glucocorticoids in the regulation of transcription factors
that control cytokine synthesis. Cytokine Growth Factor Rev, 2007. 18(1-2): p. 4556.

169.

Yang-Yen, H.F., et al., Transcriptional interference between c-Jun and the
glucocorticoid receptor: mutual inhibition of DNA binding due to direct proteinprotein interaction. Cell, 1990. 62(6): p. 1205-15.

170.

Meyer, T., J.A. Gustafsson, and J. Carlstedt-Duke, Glucocorticoid-dependent
transcriptional repression of the osteocalcin gene by competitive binding at the
TATA box. DNA Cell Biol, 1997. 16(8): p. 919-27.

171.

Shaw, G. and R. Kamen, A conserved AU sequence from the 3' untranslated region
of GM-CSF mRNA mediates selective mRNA degradation. Cell, 1986. 46(5): p.
659-67.

172.

Wilson, T. and R. Treisman, Removal of poly(A) and consequent degradation of cfos mRNA facilitated by 3' AU-rich sequences. Nature, 1988. 336(6197): p. 396-9.

173.

Peppel, K., J.M. Vinci, and C. Baglioni, The AU-rich sequences in the 3'
untranslated region mediate the increased turnover of interferon mRNA induced by
glucocorticoids. J Exp Med, 1991. 173(2): p. 349-55.

174.

Lee, S.W., et al., Glucocorticoids selectively inhibit the transcription of the
interleukin 1 beta gene and decrease the stability of interleukin 1 beta mRNA. Proc
Natl Acad Sci U S A, 1988. 85(4): p. 1204-8.

175.

Caput, D., et al., Identification of a common nucleotide sequence in the 3'untranslated region of mRNA molecules specifying inflammatory mediators. Proc
Natl Acad Sci U S A, 1986. 83(6): p. 1670-4.

176.

Mozo, L., et al., Glucocorticoids inhibit IL-4 and mitogen-induced IL-4Rα chain
expression by different posttranscriptional mechanisms. Journal of allergy and
clinical immunology, 1998. 102(6): p. 968-976.

177.

Almawi, W.Y., D.A. Hess, and M.J. Rieder, Significance of Enhanced Cytokine
Receptor Expression by Glucocorticoids. Blood, 1998. 92(10): p. 3979-3979.

91

178.

Curnow, S.J., et al., Topical glucocorticoid therapy directly induces up-regulation
of functional CXCR4 on primed T lymphocytes in the aqueous humor of patients
with uveitis. J Immunol, 2004. 172(11): p. 7154-61.

179.

Weber, M.D., et al., Blocking toll-like receptor 2 and 4 signaling during a stressor
prevents stress-induced priming of neuroinflammatory responses to a subsequent
immune challenge. Brain Behav Immun, 2013. 32: p. 112-21.

180.

Xystrakis, E., et al., Reversing the defective induction of IL-10-secreting regulatory
T cells in glucocorticoid-resistant asthma patients. J Clin Invest, 2006. 116(1): p.
146-55.

181.

Searing, D.A., et al., Decreased serum vitamin D levels in children with asthma are
associated with increased corticosteroid use. J Allergy Clin Immunol, 2010.
125(5): p. 995-1000.

182.

Zhang, Y., D.Y.M. Leung, and E. Goleva, Vitamin D Enhances Glucocorticoid
Action in Human Monocytes: INVOLVEMENT OF GRANULOCYTEMACROPHAGE COLONY-STIMULATING FACTOR AND MEDIATOR
COMPLEX SUBUNIT 14*, in J Biol Chem. 2013. p. 14544-53.

183.

Waddell, D.S., et al., The glucocorticoid receptor and FOXO1 synergistically
activate the skeletal muscle atrophy-associated MuRF1 gene. Am J Physiol
Endocrinol Metab, 2008. 295(4): p. E785-97.

184.

Majno, G. and I. Joris, Apoptosis, oncosis, and necrosis. An overview of cell death.
Am J Pathol, 1995. 146(1): p. 3-15.

185.

Fink, S.L. and B.T. Cookson, Apoptosis, pyroptosis, and necrosis: mechanistic
description of dead and dying eukaryotic cells. Infect Immun, 2005. 73(4): p. 190716.

186.

Elmore, S., Apoptosis: A Review of Programmed Cell Death. Toxicol Pathol, 2007.
35(4): p. 495-516.

187.

Eguchi, Y., et al., ATP-dependent steps in apoptotic signal transduction. Cancer
Res, 1999. 59(9): p. 2174-81.

188.

Kerr, J.F.R., A.H. Wyllie, and A.R. Currie, Apoptosis: A Basic Biological
Phenomenon with Wide-ranging Implications in Tissue Kinetics. Br J Cancer, 1972.
26(4): p. 239-57.

189.

Kurosaka, K., et al., Silent cleanup of very early apoptotic cells by macrophages. J
Immunol, 2003. 171(9): p. 4672-9.

190.

Leist, M., et al., Intracellular adenosine triphosphate (ATP) concentration: a
switch in the decision between apoptosis and necrosis. J Exp Med, 1997. 185(8):
p. 1481-6.

92

191.

Green, D.R. and J.C. Reed, Mitochondria and apoptosis. Science, 1998. 281(5381):
p. 1309-12.

192.

Li, P., et al., Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9
complex initiates an apoptotic protease cascade. Cell, 1997. 91(4): p. 479-89.

193.

Chen, G. and D.V. Goeddel, TNF-R1 signaling: a beautiful pathway. Science,
2002. 296(5573): p. 1634-5.

194.

Vaux, D.L., S. Cory, and J.M. Adams, Bcl-2 gene promotes haemopoietic cell
survival and cooperates with c-myc to immortalize pre-B cells. Nature, 1988.
335(6189): p. 440-2.

195.

Luo, X., et al., Bid, a Bcl2 interacting protein, mediates cytochrome c release from
mitochondria in response to activation of cell surface death receptors. Cell, 1998.
94(4): p. 481-90.

196.

Wei, M.C., et al., tBID, a membrane-targeted death ligand, oligomerizes BAK to
release cytochrome c. Genes Dev, 2000. 14(16): p. 2060-71.

197.

Eskes, R., et al., Bid Induces the Oligomerization and Insertion of Bax into the
Outer Mitochondrial Membrane, in Mol Cell Biol. 2000. p. 929-35.

198.

Cheng, E.H., et al., BCL-2, BCL-X(L) sequester BH3 domain-only molecules
preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol Cell, 2001.
8(3): p. 705-11.

199.

Jing, D., et al., Opposing regulation of BIM and BCL2 controls glucocorticoidinduced apoptosis of pediatric acute lymphoblastic leukemia cells. Blood, 2015.
125(2): p. 273-83.

200.

Wang, Z., et al., Microarray analysis uncovers the induction of the proapoptotic
BH3-only protein Bim in multiple models of glucocorticoid-induced apoptosis. J
Biol Chem, 2003. 278(26): p. 23861-7.

201.

Alnemri, E.S., et al., Involvement of BCL-2 in glucocorticoid-induced apoptosis of
human pre-B-leukemias. Cancer Res, 1992. 52(2): p. 491-5.

202.

Marchetti, M.C., et al., Dexamethasone-induced apoptosis of thymocytes: role of
glucocorticoid receptor-associated Src kinase and caspase-8 activation. Blood,
2003. 101(2): p. 585-93.

203.

Cifone, M.G., et al., Dexamethasone-induced thymocyte apoptosis: apoptotic
signal involves the sequential activation of phosphoinositide-specific
phospholipase C, acidic sphingomyelinase, and caspases. Blood, 1999. 93(7): p.
2282-96.

93

204.

Helmberg, A., et al., Glucocorticoid-induced apoptosis of human leukemic cells is
caused by the repressive function of the glucocorticoid receptor. EMBO J, 1995.
14(3): p. 452-60.

205.

D'Adamio, F., et al., A new dexamethasone-induced gene of the leucine zipper
family protects T lymphocytes from TCR/CD3-activated cell death. Immunity,
1997. 7(6): p. 803-12.

206.

Delfino, D.V., et al., Decrease of Bcl-xL and augmentation of thymocyte apoptosis
in GILZ overexpressing transgenic mice. Blood, 2004. 104(13): p. 4134-41.

207.

Schwartz, H.J., F.C. Lowell, and J.C. Melby, Steroid resistance in bronchial
asthma. Ann Intern Med, 1968. 69(3): p. 493-9.

208.

Nunes, C., A.M. Pereira, and M. Morais-Almeida, Asthma costs and social impact,
in Asthma Res Pract. 2017.

209.

ten Brinke, A., et al., "Refractory" eosinophilic airway inflammation in severe
asthma: effect of parenteral corticosteroids. Am J Respir Crit Care Med, 2004.
170(6): p. 601-5.

210.

Poznansky, M.C., et al., Resistance to methylprednisolone in cultures of blood
mononuclear cells from glucocorticoid-resistant asthmatic patients. Clin Sci
(Lond), 1984. 67(6): p. 639-45.

211.

Corrigan, C.J., et al., Glucocorticoid resistance in chronic asthma. Glucocorticoid
pharmacokinetics, glucocorticoid receptor characteristics, and inhibition of
peripheral blood T cell proliferation by glucocorticoids in vitro. Am Rev Respir
Dis, 1991. 144(5): p. 1016-25.

212.

Spahn, J.D., et al., Reduced glucocorticoid binding affinity in asthma is related to
ongoing allergic inflammation. Am J Respir Crit Care Med, 1995. 151(6): p. 170914.

213.

Sher, E.R., et al., Steroid-resistant asthma. Cellular mechanisms contributing to
inadequate response to glucocorticoid therapy. J Clin Invest, 1994. 93(1): p. 33-9.

214.

Matthews, J.G., et al., Defective glucocorticoid receptor nuclear translocation and
altered histone acetylation patterns in glucocorticoid-resistant patients. J Allergy
Clin Immunol, 2004. 113(6): p. 1100-8.

215.

Adcock, I.M. and P.J. Barnes, Molecular mechanisms of corticosteroid resistance.
Chest, 2008. 134(2): p. 394-401.

216.

Kino, T., Y.A. Su, and G.P. Chrousos, Human glucocorticoid receptor isoform
beta: recent understanding of its potential implications in physiology and
pathophysiology. Cell Mol Life Sci, 2009. 66(21): p. 3435-48.

94

217.

Leung, D.Y., et al., Association of glucocorticoid insensitivity with increased
expression of glucocorticoid receptor beta. J Exp Med, 1997. 186(9): p. 1567-74.

218.

Ruiz, M., et al., Characterization of two novel mutations in the glucocorticoid
receptor gene in patients with primary cortisol resistance. Clin Endocrinol (Oxf),
2001. 55(3): p. 363-71.

219.

Gottlicher, M., S. Heck, and P. Herrlich, Transcriptional cross-talk, the second
mode of steroid hormone receptor action. J Mol Med (Berl), 1998. 76(7): p. 480-9.

220.

Horwood, L.J., D.M. Fergusson, and F.T. Shannon, Social and familial factors in
the development of early childhood asthma. Pediatrics, 1985. 75(5): p. 859-68.

221.

Vink, N.M., et al., Gender differences in asthma development and remission during
transition through puberty: the TRacking Adolescents' Individual Lives Survey
(TRAILS) study. J Allergy Clin Immunol, 2010. 126(3): p. 498-504.e1-6.

222.

Arshad, S.H., et al., Pathophysiological characterization of asthma transitions
across adolescence, in Respir Res. 2014.

223.

Fleisher, B., et al., Lung profile: sex differences in normal pregnancy. Obstet
Gynecol, 1985. 66(3): p. 327-30.

224.

Doershuk, C.F., B.J. Fisher, and L.W. Matthews, Specific airway resistance from
the perinatal period into adulthood. Alterations in childhood pulmonary disease.
Am Rev Respir Dis, 1974. 109(4): p. 452-7.

225.

Thurlbeck, W.M., Postnatal human lung growth. Thorax, 1982. 37(8): p. 564-71.

226.

Nielsen, H.C., H.M. Zinman, and J.S. Torday, Dihydrotestosterone inhibits fetal
rabbit pulmonary surfactant production. J Clin Invest, 1982. 69(3): p. 611-6.

227.

Gross, I., et al., The influence of hormones on the biochemical development of fetal
rat lung in organ culture. I. Estrogen. Biochim Biophys Acta, 1979. 575(3): p. 37583.

228.

Patel, M., et al., Predictors of severe exacerbations, poor asthma control, and βagonist overuse for patients with asthma. J Allergy Clin Immunol Pract, 2014. 2(6):
p. 751-8.

229.

Chen, Y., et al., Obesity May Increase the Incidence of Asthma in Women but Not
in Men: Longitudinal Observations from the Canadian National Population Health
Surveys. American Journal of Epidemiology, 2002. 155(3): p. 191-197.

230.

Moore, W.C., et al., Identification of asthma phenotypes using cluster analysis in
the Severe Asthma Research Program. Am J Respir Crit Care Med, 2010. 181(4):
p. 315-23.

95

231.

Wu, W., et al., Unsupervised phenotyping of Severe Asthma Research Program
participants using expanded lung data. J Allergy Clin Immunol, 2014. 133(5): p.
1280-8.

232.

Siiteri, P.K., Adipose tissue as a source of hormones. Am J Clin Nutr, 1987. 45(1
Suppl): p. 277-82.

233.

Quek, Y.W., et al., Associations of serum leptin with atopic asthma and allergic
rhinitis in children. Am J Rhinol Allergy, 2010. 24(5): p. 354-8.

234.

Schatz, M., et al., Asthma exacerbation rates in adults are unchanged over a 5-year
period despite high-intensity therapy. J Allergy Clin Immunol Pract, 2014. 2(5): p.
570-4.e1.

235.

Sears, M.R., et al., A longitudinal, population-based, cohort study of childhood
asthma followed to adulthood. N Engl J Med, 2003. 349(15): p. 1414-22.

236.

Mohan, S.S., et al., Higher serum testosterone and dihydrotestosterone, but not
oestradiol, are independently associated with favourable indices of lung function
in community-dwelling men. Clin Endocrinol (Oxf), 2015. 83(2): p. 268-76.

237.

Hayashi, T., et al., Less sensitivity for late airway inflammation in males than
females in BALB/c mice. Scand J Immunol, 2003. 57(6): p. 562-7.

238.

Becerra-Diaz, M., et al., Androgen and Androgen Receptor as Enhancers of M2
Macrophage Polarization in Allergic Lung Inflammation. J Immunol, 2018.
201(10): p. 2923-2933.

239.

Laffont, S., et al., Androgen signaling negatively controls group 2 innate lymphoid
cells. J Exp Med, 2017. 214(6): p. 1581-1592.

240.

Laffont, S., et al., Androgen signaling negatively controls group 2 innate lymphoid
cells. J Exp Med, 2017. 214(6): p. 1581-1592.

241.

Cephus, J.Y., et al., Testosterone Attenuates Group 2 Innate Lymphoid CellMediated Airway Inflammation. Cell Rep, 2017. 21(9): p. 2487-2499.

242.

Fuseini, H., et al., Testosterone Decreases House Dust Mite-Induced Type 2 and
IL-17A-Mediated Airway Inflammation. J Immunol, 2018. 201(7): p. 1843-1854.

243.

Stanford, K.I., et al., Influence of menstrual cycle phase on pulmonary function in
asthmatic athletes. Eur J Appl Physiol, 2006. 96(6): p. 703-10.

244.

Driver, H.S., et al., The influence of the menstrual cycle on upper airway resistance
and breathing during sleep. Sleep, 2005. 28(4): p. 449-56.

245.

Hawkins, S.M. and M.M. Matzuk, The menstrual cycle: basic biology. Ann N Y
Acad Sci, 2008. 1135: p. 10-8.

96

246.

Hanley, S.P., Asthma variation with menstruation. Br J Dis Chest, 1981. 75(3): p.
306-8.

247.

Gibbs, C.J., et al., Premenstrual exacerbation of asthma. Thorax, 1984. 39(11): p.
833-6.

248.

Tan, K.S., L.C. McFarlane, and B.J. Lipworth, Loss of normal cyclical beta 2
adrenoceptor regulation and increased premenstrual responsiveness to adenosine
monophosphate in stable female asthmatic patients. Thorax, 1997. 52(7): p. 60811.

249.

Salam, M.T., M. Wenten, and F.D. Gilliland, Endogenous and exogenous sex
steroid hormones and asthma and wheeze in young women. J Allergy Clin
Immunol, 2006. 117(5): p. 1001-7.

250.

Tan, K.S., L.C. McFarlane, and B.J. Lipworth, Modulation of airway reactivity and
peak flow variability in asthmatics receiving the oral contraceptive pill. Am J
Respir Crit Care Med, 1997. 155(4): p. 1273-7.

251.

Schatz, M., et al., Asthma morbidity during pregnancy can be predicted by severity
classification. J Allergy Clin Immunol, 2003. 112(2): p. 283-8.

252.

Wang, H., N. Li, and H. Huang, Asthma in Pregnancy: Pathophysiology,
Diagnosis, Whole-Course Management, and Medication Safety. Can Respir J,
2020. 2020: p. 9046842.

253.

Wegmann, T.G., et al., Bidirectional cytokine interactions in the maternal-fetal
relationship: is successful pregnancy a TH2 phenomenon? Immunol Today, 1993.
14(7): p. 353-6.

254.

Saito, S., et al., Quantitative analysis of peripheral blood Th0, Th1, Th2 and the
Th1:Th2 cell ratio during normal human pregnancy and preeclampsia. Clin Exp
Immunol, 1999. 117(3): p. 550-5.

255.

Schatz, M., et al., The course of asthma during pregnancy, post partum, and with
successive pregnancies: a prospective analysis. J Allergy Clin Immunol, 1988.
81(3): p. 509-17.

256.

Lao, T.T. and M. Huengsburg, Labour and delivery in mothers with asthma. Eur J
Obstet Gynecol Reprod Biol, 1990. 35(2-3): p. 183-90.

257.

Gelber, M., et al., Uncontrollable life-threatening status asthmaticus--an indicator
for termination of pregnancy by cesarean section. Respiration, 1984. 46(3): p. 3202.

258.

Shanies, H.M., M.T. Venkataraman, and T. Peter, Reversal of intractable acute
severe asthma by first-trimester termination of pregnancy. J Asthma, 1997. 34(2):
p. 169-72.

97

259.

Troisi, R.J., et al., Menopause, postmenopausal estrogen preparations, and the risk
of adult-onset asthma. A prospective cohort study. Am J Respir Crit Care Med,
1995. 152(4 Pt 1): p. 1183-8.

260.

Romieu, I., et al., Postmenopausal hormone therapy and asthma onset in the E3N
cohort. Thorax, 2010. 65(4): p. 292-7.

261.

Cai, Y., J. Zhou, and D.C. Webb, Estrogen stimulates Th2 cytokine production and
regulates the compartmentalisation of eosinophils during allergen challenge in a
mouse model of asthma. Int Arch Allergy Immunol, 2012. 158(3): p. 252-60.

262.

Semik-Orzech, A., S. Skoczynski, and W. Pierzchala, Serum estradiol
concentration, estradiol-to-progesterone ratio and sputum IL-5 and IL-8
concentrations are increased in luteal phase of the menstrual cycle in
perimenstrual asthma patients. Eur Ann Allergy Clin Immunol, 2017. 49(4): p.
161-170.

263.

Sakai, T., et al., The soy isoflavone equol enhances antigen-specific IgE production
in ovalbumin-immunized BALB/c mice. J Nutr Sci Vitaminol (Tokyo), 2010. 56(1):
p. 72-6.

264.

Uemura, Y., et al., 17 Beta-estradiol (E2) plus tumor necrosis factor-alpha induces
a distorted maturation of human monocyte-derived dendritic cells and promotes
their capacity to initiate T-helper 2 responses. Hum Immunol, 2008. 69(3): p. 14957.

265.

Cocchiara, R., et al., Modulation of rat peritoneal mast cell and human basophil
histamine release by estrogens. Int Arch Allergy Appl Immunol, 1990. 93(2-3): p.
192-7.

266.

Cocchiara, R., et al., Oestradiol enhances in vitro the histamine release induced by
embryonic histamine-releasing factor (EHRF) from uterine mast cells. Hum
Reprod, 1992. 7(8): p. 1036-41.

267.

Jing, H., Z. Wang, and Y. Chen, Effect of oestradiol on mast cell number and
histamine level in the mammary glands of rat. Anat Histol Embryol, 2012. 41(3):
p. 170-6.

268.

Tam, A., et al., Estradiol Increases Mucus Synthesis in Bronchial Epithelial Cells,
in PLoS One. 2014.

269.

Huber, S.A., J. Kupperman, and M.K. Newell, Estradiol prevents and testosterone
promotes Fas-dependent apoptosis in CD4+ Th2 cells by altering Bcl 2 expression.
Lupus, 1999. 8(5): p. 384-7.

270.

Helguero, L.A., et al., Estrogen receptors alfa (ERalpha) and beta (ERbeta)
differentially regulate proliferation and apoptosis of the normal murine mammary
epithelial cell line HC11. Oncogene, 2005. 24(44): p. 6605-16.

98

271.

Frasor, J., et al., Profiling of estrogen up- and down-regulated gene expression in
human breast cancer cells: insights into gene networks and pathways underlying
estrogenic control of proliferation and cell phenotype. Endocrinology, 2003.
144(10): p. 4562-74.

272.

Frasor, J., et al., Positive cross-talk between estrogen receptor and NF-kappaB in
breast cancer. Cancer Res, 2009. 69(23): p. 8918-25.

273.

Samavat, H. and M.S. Kurzer, Estrogen metabolism and breast cancer. Cancer
Lett, 2015. 356(2 Pt A): p. 231-43.

274.

Levitz, M., S. Kadner, and B.K. Young, Intermediary metabolism of estriol in
pregnancy. J Steroid Biochem, 1984. 20(4b): p. 971-4.

275.

Schwers, J., et al., Metabolism of oestrone sulphate by the previable human foetus.
Acta Endocrinol (Copenh), 1965. 50(4): p. 597-610.

276.

Watson, C.S., Y.J. Jeng, and M.Y. Kochukov, Nongenomic actions of estradiol
compared with estrone and estriol in pituitary tumor cell signaling and
proliferation, in FASEB J. 2008. p. 3328-36.

277.

Jensen, E.V., Basic guides to the mechanism of estrogen action. Recent Progr
Hormone Res, 1962. 18: p. 387-414.

278.

Kuiper, G.G., et al., Cloning of a novel receptor expressed in rat prostate and
ovary. Proc Natl Acad Sci U S A, 1996. 93(12): p. 5925-30.

279.

Filardo, E., et al., Activation of the novel estrogen receptor G protein-coupled
receptor 30 (GPR30) at the plasma membrane. Endocrinology, 2007. 148(7): p.
3236-45.

280.

Gosden, J.R., P.G. Middleton, and D. Rout, Localization of the human oestrogen
receptor gene to chromosome 6q24----q27 by in situ hybridization. Cytogenet Cell
Genet, 1986. 43(3-4): p. 218-20.

281.

Enmark, E., et al., Human estrogen receptor beta-gene structure, chromosomal
localization, and expression pattern. J Clin Endocrinol Metab, 1997. 82(12): p.
4258-65.

282.

Filardo, E.J. and P. Thomas, Minireview: G Protein-Coupled Estrogen Receptor-1,
GPER-1: Its Mechanism of Action and Role in Female Reproductive Cancer, Renal
and Vascular Physiology, in Endocrinology. 2012. p. 2953-62.

283.

Nilsson, S., et al., Mechanisms of estrogen action. Physiol Rev, 2001. 81(4): p.
1535-65.

99

284.

Klein-Hitpass, L., et al., An estrogen-responsive element derived from the 5'
flanking region of the Xenopus vitellogenin A2 gene functions in transfected human
cells. Cell, 1986. 46(7): p. 1053-61.

285.

Paech, K., et al., Differential ligand activation of estrogen receptors ERalpha and
ERbeta at AP1 sites. Science, 1997. 277(5331): p. 1508-10.

286.

O'Lone, R., et al., Genomic targets of nuclear estrogen receptors. Mol Endocrinol,
2004. 18(8): p. 1859-75.

287.

Gaub, M.P., et al., Activation of the ovalbumin gene by the estrogen receptor
involves the fos-jun complex. Cell, 1990. 63(6): p. 1267-76.

288.

Porter, W., et al., Functional synergy between the transcription factor Sp1 and the
estrogen receptor. Mol Endocrinol, 1997. 11(11): p. 1569-80.

289.

Filardo, E.J., et al., Estrogen-induced activation of Erk-1 and Erk-2 requires the G
protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the
epidermal growth factor receptor through release of HB-EGF. Mol Endocrinol,
2000. 14(10): p. 1649-60.

290.

Mollerup, S., et al., Expression of estrogen receptors alpha and beta in human lung
tissue and cell lines. Lung Cancer, 2002. 37(2): p. 153-9.

291.

Dijkstra, A., et al., Estrogen receptor 1 polymorphisms are associated with airway
hyperresponsiveness and lung function decline, particularly in female subjects with
asthma. J Allergy Clin Immunol, 2006. 117(3): p. 604-11.

292.

Riffo-Vasquez, Y., et al., Role of sex hormones in allergic inflammation in mice.
Clin Exp Allergy, 2007. 37(3): p. 459-70.

293.

Zaitsu, M., et al., Estradiol activates mast cells via a non-genomic estrogen
receptor-α and calcium influx. Mol Immunol, 2007. 44(8): p. 1977-85.

294.

Ambhore, N.S., et al., Estrogen Receptor Beta Signaling Inhibits PDGF Induced
Human Airway Smooth Muscle Proliferation. Mol Cell Endocrinol, 2018. 476: p.
37-47.

295.

Shah, S., P. Gohil, and G. Shah, Role of Estrogen Receptor-α in an Experimental
Model of Bronchial Asthma, in Iran Biomed J. 2010. p. 41-8.

296.

Da Silva, J.A., Sex hormones and glucocorticoids: interactions with the immune
system. Ann N Y Acad Sci, 1999. 876: p. 102-17; discussion 117-8.

297.

Krishnan, A.V., S. Swami, and D. Feldman, Estradiol inhibits glucocorticoid
receptor expression and induces glucocorticoid resistance in MCF-7 human breast
cancer cells. J Steroid Biochem Mol Biol, 2001. 77(1): p. 29-37.

100

298.

Hall, R.E., et al., Steroid hormone receptor gene expression in human breast cancer
cells: inverse relationship between oestrogen and glucocorticoid receptor
messenger RNA levels. Int J Cancer, 1990. 46(6): p. 1081-7.

299.

Zhang, Y., et al., Estrogen inhibits glucocorticoid action via protein phosphatase
5 (PP5)-mediated glucocorticoid receptor dephosphorylation. J Biol Chem, 2009.
284(36): p. 24542-52.

300.

Ying, S., et al., Thymic stromal lymphopoietin expression is increased in asthmatic
airways and correlates with expression of Th2-attracting chemokines and disease
severity. J Immunol, 2005. 174(12): p. 8183-90.

301.

Zhou, F., et al., Non-classical antiestrogenic actions of dexamethasone in variant
MCF-7 human breast cancer cells in culture. Mol Cell Endocrinol, 1989. 66(2): p.
189-97.

302.

Gallagher, J.C., et al., Combination treatment with estrogen and calcitriol in the
prevention of age-related bone loss. J Clin Endocrinol Metab, 2001. 86(8): p. 361828.

303.

Rackoff, P.J. and C.J. Rosen, Pathogenesis and treatment of glucocorticoidinduced osteoporosis. Drugs Aging, 1998. 12(6): p. 477-84.

304.

Meyer, M.E., et al., Steroid hormone receptors compete for factors that mediate
their enhancer function. Cell, 1989. 57(3): p. 433-42.

305.

Karmakar, S., Y. Jin, and A.K. Nagaich, Interaction of glucocorticoid receptor
(GR) with estrogen receptor (ER) alpha and activator protein 1 (AP1) in
dexamethasone-mediated interference of ERalpha activity. J Biol Chem, 2013.
288(33): p. 24020-34.

306.

Yang, F., et al., Glucocorticoid Receptor:MegaTrans Switching Mediates the
Repression of an ERalpha-Regulated Transcriptional Program. Mol Cell, 2017.
66(3): p. 321-331.e6.

307.

Whirledge, S. and J.A. Cidlowski, Estradiol antagonism of glucocorticoid-induced
GILZ expression in human uterine epithelial cells and murine uterus.
Endocrinology, 2013. 154(1): p. 499-510.

308.

Fuentes, N. and P. Silveyra, Estrogen receptor signaling mechanisms. Adv Protein
Chem Struct Biol, 2019. 116: p. 135-70.

309.

Cuzzocrea, S., et al., Estrogen receptor antagonist fulvestrant (ICI 182,780)
inhibits the anti-inflammatory effect of glucocorticoids. Mol Pharmacol, 2007.
71(1): p. 132-44.

101

310.

Miranda, T.B., et al., Reprogramming the chromatin landscape: interplay of the
estrogen and glucocorticoid receptors at the genomic level. Cancer Res, 2013.
73(16): p. 5130-9.

311.

West, D.C., et al., GR and ER Coactivation Alters the Expression of Differentiation
Genes and Associates with Improved ER+ Breast Cancer Outcome. Mol Cancer
Res, 2016. 14(8): p. 707-19.

312.

Shah, R. and D.C. Newcomb, Sex Bias in Asthma Prevalence and Pathogenesis.
Front Immunol, 2018. 9.

313.

Vahrenkamp, J.M., et al., Clinical and Genomic Crosstalk between Glucocorticoid
Receptor and Estrogen Receptor α In Endometrial Cancer. Cell Rep, 2018. 22(11):
p. 2995-3005.

314.

Bolt, M.J., et al., Coactivators enable glucocorticoid receptor recruitment to finetune estrogen receptor transcriptional responses, in Nucleic Acids Res. 2013. p.
4036-48.

315.

Lew, M., Good statistical practice in pharmacology. Problem 2. Br J Pharmacol,
2007. 152(3): p. 299-303.

316.

Carstensen-Kirberg, M., et al., Sfrp5 increases glucose-stimulated insulin secretion
in the rat pancreatic beta cell line INS-1E. PLoS One, 2019. 14(3): p. e0213650.

317.

Bredo, G., et al., Interleukin-25 initiates Th2 differentiation of human CD4(+) T
cells and influences expression of its own receptor. Immun Inflamm Dis, 2015.
3(4): p. 455-68.

318.

MacLean Scott, E., et al., Activation of Th2 cells downregulates CRTh2 through an
NFAT1 mediated mechanism. PLoS One, 2018. 13(7): p. e0199156.

319.

Luchak, A., et al., Comparative efficacy of glucocorticoid receptor agonists on Th2
cell function and attenuation by progesterone. BMC Immunol, 2020. 21(1): p. 54.

320.

Kanagalingam, T., et al., IL-2 modulates Th2 cell responses to glucocorticosteroid:
A cause of persistent type 2 inflammation? Immun Inflamm Dis, 2019. 7(3): p. 112124.

321.

Sundrud, M.S., et al., Genetic Reprogramming of Primary Human T Cells Reveals
Functional Plasticity in Th Cell Differentiation. The Journal of Immunology, 2003.
171(7): p. 3542-3549.

322.

De Fanis, U., et al., GATA3 up-regulation associated with surface expression of
CD294/CRTH2: a unique feature of human Th cells, in Blood. 2007. p. 4343-50.

323.

Mjosberg, J., et al., The transcription factor GATA3 is essential for the function of
human type 2 innate lymphoid cells. Immunity, 2012. 37(4): p. 649-59.

102

324.

Ekert, P.G., J. Silke, and D.L. Vaux, Caspase inhibitors. Cell Death Differ, 1999.
6(11): p. 1081-6.

325.

Man, S.M. and T.D. Kanneganti, Converging roles of caspases in inflammasome
activation, cell death and innate immunity. Nat Rev Immunol, 2016. 16(1): p. 7-21.

326.

Chaudhri, R.A., et al., Estrogen Receptor-alpha 36 Mediates the Anti-apoptotic
Effect of Estradiol in Triple Negative Breast Cancer Cells via a MembraneAssociated Mechanism. Biochim Biophys Acta, 2014. 1843(11): p. 2796-806.

327.

D'Astous, M., et al., Implication of the phosphatidylinositol-3 kinase/protein kinase
B signaling pathway in the neuroprotective effect of estradiol in the striatum of 1methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice. Mol Pharmacol, 2006. 69(4): p.
1492-8.

328.

Volkmann, N., et al., The rheostat in the membrane: BCL-2 family proteins and
apoptosis. Cell Death Differ, 2014. 21(2): p. 206-15.

329.

Ploner, C., et al., The BCL2 rheostat in glucocorticoid-induced apoptosis of acute
lymphoblastic leukemia. Leukemia, 2008. 22(2): p. 370-7.

330.

Gruver-Yates, A.L. and J.A. Cidlowski, Tissue-specific actions of glucocorticoids
on apoptosis: a double-edged sword. Cells, 2013. 2(2): p. 202-23.

331.

Fan, L., S.C. Pandey, and R.S. Cohen, Estrogen affects levels of Bcl-2 protein and
mRNA in medial amygdala of ovariectomized rats. J Neurosci Res, 2008. 86(16):
p. 3655-64.

332.

Acconcia, F., et al., Survival versus apoptotic 17beta-estradiol effect: role of ER
alpha and ER beta activated non-genomic signaling. J Cell Physiol, 2005. 203(1):
p. 193-201.

333.

Lewis-Wambi, J.S. and V.C. Jordan, Estrogen regulation of apoptosis: how can
one hormone stimulate and inhibit?, in Breast Cancer Res. 2009. p. 206.

334.

Beatson, G.T., On the Treatment of Inoperable Cases of Carcinoma of the Mamma:
Suggestions for a New Method of Treatment, with Illustrative Cases. Trans Med
Chir Soc Edinb, 1896. 15: p. 153-179.

335.

Russo, I.H. and J. Russo, Role of hormones in mammary cancer initiation and
progression. J Mammary Gland Biol Neoplasia, 1998. 3(1): p. 49-61.

336.

Tamoxifen for early breast cancer: an overview of the randomised trials. Early
Breast Cancer Trialists' Collaborative Group. Lancet, 1998. 351(9114): p. 145167.

337.

Michl, J., K.C. Park, and P. Swietach, Evidence-based guidelines for controlling
pH in mammalian live-cell culture systems, in Commun Biol. 2019.

103

338.

Salem, M.L., Estrogen, a double-edged sword: modulation of TH1- and TH2mediated inflammations by differential regulation of TH1/TH2 cytokine
production. Curr Drug Targets Inflamm Allergy, 2004. 3(1): p. 97-104.

339.

Dufour, J.M., et al., Sertoli cell line lacks the immunoprotective properties
associated with primary Sertoli cells. Cell Transplant, 2008. 17(5): p. 525-34.

340.

Kaur, G. and J.M. Dufour, Cell lines: Valuable tools or useless artifacts, in
Spermatogenesis. 2012. p. 1-5.

341.

Moharram, S.A., K. Shah, and J.U. Kazi, T-cell Acute Lymphoblastic Leukemia
Cells Display Activation of Different Survival Pathways. J Cancer, 2017. 8(19): p.
4124.

342.

Yue, L., et al., Prostaglandin D2 induces apoptosis of human osteoclasts by
activating the CRTH2 receptor and the intrinsic apoptosis pathway. Bone, 2012.
51(3): p. 338-46.

343.

Chen, Y.C., S.C. Shen, and S.H. Tsai, Prostaglandin D(2) and J(2) induce
apoptosis in human leukemia cells via activation of the caspase 3 cascade and
production of reactive oxygen species. Biochim Biophys Acta, 2005. 1743(3): p.
291-304.

344.

Wang, J.J. and O.T. Mak, Induction of apoptosis in non-small cell lung carcinoma
A549 cells by PGD₂ metabolite, 15d-PGJ₂. Cell Biol Int, 2011. 35(11): p. 1089-96.

345.

Miranda, T.B., et al., Reprogramming the Chromatin Landscape: interplay of the
estrogen and glucocorticoid receptors at the genomic level. Cancer Res, 2013.
73(16): p. 5130-9.

346.

Joanny, E., et al., Anti-inflammatory effects of selective glucocorticoid receptor
modulators are partially dependent on up-regulation of dual specificity
phosphatase 1. Br J Pharmacol, 2012. 165(4b): p. 1124-36.

347.

Clark, A.R., Anti-inflammatory functions of glucocorticoid-induced genes. Mol
Cell Endocrinol, 2007. 275(1-2): p. 79-97.

348.

Duque Ede, A. and C.D. Munhoz, The Pro-inflammatory Effects of Glucocorticoids
in the Brain. Front Endocrinol (Lausanne), 2016. 7.

349.

Sorrells, S.F., et al., The Stressed CNS: When Glucocorticoids Aggravate
Inflammation. Neuron, 2009. 64(1): p. 33-9.

350.

Madrigal, J.L., et al., Induction of cyclooxygenase-2 accounts for restraint stressinduced oxidative status in rat brain. Neuropsychopharmacology, 2003. 28(9): p.
1579-88.

104

351.

Madrigal, J.L., et al., Inducible nitric oxide synthase expression in brain cortex
after acute restraint stress is regulated by nuclear factor kappaB-mediated
mechanisms. J Neurochem, 2001. 76(2): p. 532-8.

352.

Madrigal, J.L., et al., The increase in TNF-alpha levels is implicated in NF-kappaB
activation and inducible nitric oxide synthase expression in brain cortex after
immobilization stress. Neuropsychopharmacology, 2002. 26(2): p. 155-63.

353.

Pérez-Nievas, B.G., et al., Corticosterone as a marker of susceptibility to
oxidative/nitrosative cerebral damage after stress exposure in rats.
Psychoneuroendocrinology, 2007. 32(6): p. 703-11.

354.

Czock, D., et al., Pharmacokinetics and pharmacodynamics of systemically
administered glucocorticoids. Clin Pharmacokinet, 2005. 44(1): p. 61-98.

355.

Panesar, N.S., et al., Lymphopenia and neutrophilia in SARS are related to the
prevailing serum cortisol, in Eur J Clin Invest. 2004. p. 382-4.

356.

Voss, T.C., et al., Dynamic Exchange at Regulatory Elements during Chromatin
Remodeling Underlies Assisted Loading Mechanism. Cell, 2011. 146(4): p. 544-54.

357.

Cvoro, A., et al., Cross talk between glucocorticoid and estrogen receptors occurs
at a subset of proinflammatory genes. J Immunol, 2011. 186(7): p. 4354-60.

358.

Reddy, T.E., et al., Genomic determination of the glucocorticoid response reveals
unexpected mechanisms of gene regulation. Genome Res, 2009. 19(12): p. 216371.

359.

Phillips, J.E. and V.G. Corces, CTCF: Master Weaver of the Genome. Cell, 2009.
137(7): p. 1194-211.

360.

Qureshi, F., A. Zaritsky, and M.P. Poirier, Comparative efficacy of oral
dexamethasone versus oral prednisone in acute pediatric asthma. J Pediatr, 2001.
139(1): p. 20-6.

361.

Kravitz, J., et al., Two days of dexamethasone versus 5 days of prednisone in the
treatment of acute asthma: a randomized controlled trial. Ann Emerg Med, 2011.
58(2): p. 200-4.

362.

Harrington, W.R., et al., Activities of estrogen receptor alpha- and beta-selective
ligands at diverse estrogen responsive gene sites mediating transactivation or
transrepression. Mol Cell Endocrinol, 2003. 206(1-2): p. 13-22.

363.

Martin, V.T. and M. Behbehani, Ovarian hormones and migraine headache:
understanding mechanisms and pathogenesis--part 2. Headache, 2006. 46(3): p.
365-86.

105

364.

Mishell, D.R., Jr., et al., Serum estradiol in women ingesting combination oral
contraceptive steroids. Am J Obstet Gynecol, 1972. 114(7): p. 923-8.

365.

Stricker, R., et al., Establishment of detailed reference values for luteinizing
hormone, follicle stimulating hormone, estradiol, and progesterone during
different phases of the menstrual cycle on the Abbott ARCHITECT analyzer. Clin
Chem Lab Med, 2006. 44(7): p. 883-7.

366.

Louizos, C., et al., Understanding the hysteresis loop conundrum in
pharmacokinetic/pharmacodynamic relationships. J Pharm Pharm Sci, 2014.
17(1): p. 34-91.

367.

Sykes, D.A., et al., Fevipiprant (QAW039), a Slowly Dissociating CRTh2
Antagonist with the Potential for Improved Clinical Efficacy. Mol Pharmacol,
2016. 89(5): p. 593-605.

368.

Bateman, E.D., et al., Fevipiprant, an oral prostaglandin DP(2) receptor (CRTh2)
antagonist, in allergic asthma uncontrolled on low-dose inhaled corticosteroids.
Eur Respir J, 2017. 50(2).

369.

Gonem, S., et al., Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in
patients with persistent eosinophilic asthma: a single-centre, randomised, doubleblind, parallel-group, placebo-controlled trial. Lancet Respir Med, 2016. 4(9): p.
699-707.

370.

Brightling, C.E., et al., Effectiveness of fevipiprant in reducing exacerbations in
patients with severe asthma (LUSTER-1 and LUSTER-2): two phase 3 randomised
controlled trials. Lancet Respir Med, 2020.

371.

Ortega, H.G., et al., Mepolizumab treatment in patients with severe eosinophilic
asthma. N Engl J Med, 2014. 371(13): p. 1198-207.

106

Appendices
Data generated by former members of Dr. Lisa Cameron’s laboratory in collaboration with
Dr. Shrestha Palikhe at University of Alberta. The following data in combination with my
data is contributing to a manuscript in preparation.

Appendix 1.1: Proportion of Th2 Cells in Men and Women with Severe Asthma
CRTh2 surface staining in circulating peripheral whole blood cells of asthmatics at Asthma
Clinic at University of Alberta separated by sex and asthma phenotype (mild/moderate or
severe). Data represented as mean ± SEM and statistical significance,* indicating P<0.05
vs control, was determined through one-way repeated measures ANOVA. Data was
assessed by flow cytometry and generated by Dr. Nami Shrestha Palikhe and Dr. Lisa
Cameron.
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Appendix 1.2: Correlation Between ICS and Th2 Cells Separated by Sex
Relationship between daily dosage of inhaled corticosteroid (µg) and proportion of Th2
cells in circulating peripheral whole blood cells as measured by flow cytometry in males
(A) or females (B). Data was analyzed through Pearson’s correlation coefficient and
generated by Dr. Nami Shrestha Palikhe and Dr. Lisa Cameron.
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Appendix 1.3: CRTh2 RNA and Protein Levels in Response to GC and ERa Agonist
Co-treatment in Primary Th2 Cells
Primary Th2 cells were treated for 24 hours with DEX and/or PPT. Total CRTh2 mRNA
was measured through qRT-PCR, using 2-DDCt, normalized to GAPDH (A). Through
western blot analysis, CRTh2 total protein abundance was measured through densitometry
and normalized to GAPDH (n=3) (B). Statistical differences represented through asterisks
(*) indicating significance vs control (P<0.05). Data generated by Dr. Lauren Solomon and
Meerah Vijeyakumaran.
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Appendix 3.1: Gating Strategy of Apoptotic Th2 Cells
Line2 4_1 ppt + 01 dex_006.fcs

Primary Th2
cells were treated for 48 hours with 0.1 µM DEX and 1.0 µM PPT. Through
P2
39016

flow cytometry, percept of Alexa FluorTM 647 Annexin V conjugate (Annexin V+; A) and
7-AAD+ (B) stained cells were measured. Further analysis through FlowJo computer
software allowed for the determination of percent of cells in an apoptotic state, Annexin
V+/7-AAD– (C) through quadrant gating. Annexin V+/7-AAD+ cells are in quadrant 1,
Annexin V+/7-AAD+ cells in quadrant 2, Annexin V+/7-AAD- cells in quadrant 3, and
Annexin V-/7-AAD- cells are in quadrant 4. This is a representative figure from one
experiment that is used to explain the gating analysis used throughout all experiments.
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Appendix 4.1: Variation in CRTh2 mRNA amongst CRTh2-6388G>A within Males
and Females
CRTh2 mRNA measured through qRT-PCR of whole blood of severe asthmatic patients.
Data normalized to GAPDH and presented as fold change. Patients were sorted by
genotype and sex. Significance (*) represents differences between condition and control
(P<0.05). Data was generated by Drs. Nami Shrestha Palikhe and Lisa Cameron.
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